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 By definition, gene therapy is the delivery of genetic material to produce a 
therapeutic effect.  Interest has increased in using embryonic stem (ES) cells as targets 
for gene therapy.  Their properties of self-renewal, clonogenicity, and pluripotentiality 
give ES cells the potential to be an unlimited source of cells for cell replacement therapy 
particularly suitable for genetic modification.  Recombinant retroviruses are common 
vehicles for genetic modification, as they accurately and stably integrate the gene of 
interest into the target cell genome and theoretically offer long-term therapy.   
 To respond to the nation’s desperate need to solve its critical shortage of 
donated pancreata for transplantation, the long-term goal of current tissue engineering 
research is to generate physiologically functional insulin-producing cells for alleviation of 
the complications of type 1 diabetes.  However, these efforts have been limited by the 
inability to generate large numbers of cells suitable for transplantation.  The original 
objective of this proposal was to address this cell source limitation by investigating the 
genetic modification of murine embryonic stem (mES) cells.  We hypothesized that 
sustained ectopic expression of proendocrine transcription factor neurogenin 3 (ngn3) in 
mES cells would be an efficient trigger to enhance the differentiation and beta cell 
functionality of ES cells. 
 However, genetically modifying ES cells to generate insulin-producing cells and 
to elucidate the mystery of the endocrine pancreas lineage has proven difficult due to the 
mechanisms ES cells employ to silence retrovirus gene expression.  We found that 
expression of ngn3 and the enhanced green fluorescent protein (eGFP) reporter gene 
were both significantly silenced in genetically modified mES cells.  Therefore, the 
objectives of this thesis were redirected to overcome this obstacle and enhance the 
 x
efficiency of transduction in ES cells and to identify any additional restrictions in gene 
transfer to ES cells.   
 We first investigated whether delivering more transgenes would improve 
retroviral gene transfer to murine embryonic stem (mES) cells.  We formed polymer 
complexes with MSCV-derived ecotropic retroviruses, concentrated them up to 40-fold, 
and transduced two different murine embryonic stem cell lines, and a mouse fibroblast 
cell line as a control.  The number of integrated transgenes increased more than 50-fold 
in the embryonic stem cell lines, yet, surprisingly, transgene expression did not increase.  
Interestingly, the embryonic stem cells had significantly fewer integrated transgenes than 
the mouse fibroblasts, even though transduction conditions were identical, which 
suggests that embryonic stem cells may be restricted in more than one step of retrovirus 
transduction.   
We next investigated which steps of the virus lifecycle restrict efficient 
transduction of ES cells.  Using recombinant MMuLV-derived retrovirus and recombinant 
HIV-1-derived lentivirus, we compared three major steps in the transduction of R1 mES 
and NIH 3T3 cells: 1) the number of active virus particles that adsorb to cells in a given 
absorption time; 2) the number of integrated transgenes; and 3) the corresponding level 
of gene expression.  We found that retroviruses and lentiviruses similarly bind 3 or 4-fold 
less efficiently to R1 mES cells than to NIH 3T3 cells.  R1 mES cells integrated 3-fold 
fewer retrovirus transgenes than NIH 3T3 cells and showed 11-fold lower retrovirus 
transgene expression levels.  In comparison, R1 mES cells integrated 10-fold fewer 
lentivirus transgenes than NIH 3T3 cells and showed 8-fold lower lentivirus transgene 
expression levels.  Although silencing remains the biggest obstacle to retroviral gene 
transfer, these results indicate virus binding and integration in the transduction process 
are also limiting in ES cells.   
 xi
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We also investigated whether depletion of linker histone 1 in ES cells would 
alleviate silencing of retrovirus transgenes and improve gene transfer.  To study the role 
of H1 in retroviral gene transfer, we transduced histone H1c, H1d, H1e triple null mouse 
embryonic stem cells with three different recombinant vectors – murine embryonic stem 
cell retrovirus (MSCV), and SIV and HIV-1 derived lentiviruses.  We found that 
transduction of mES cells depleted of histone H1 did not improve viral gene transfer, and 
triple null mES cells had about a 2-fold reduction in the number of eGFP+ cells for all 
three viruses in comparison to wild-type mES cells.   
In summary, we applied methods to overcome the major obstacle of retrovirus 
gene silencing and identified additional restrictions in retroviral gene transfer.  This 
research is significant for improving protocols for gene transfer to ES cells and 













Diabetes, affecting over 125 million people worldwide and 16 million in the US, is 
a disease where the patient exhibits relative or absolute insulin deficiency, resulting in 
many pathological manifestations including renal failure, retinopathy, neuropathy, and 
extremity amputation [1-6].  Complete autoimmune destruction of pancreatic beta cells 
characterizes type I diabetes, also known as insulin-dependent diabetes mellitus (IDDM) 
[5]. The patient’s pancreatic beta cells can no longer produce insulin in response to high 
blood glucose levels following meals [5]. The major clinical problems of type I diabetes 
are due to the long-term effects of chronic hyperglycemia [4].  Patients with diabetes 
suffer from hyperglycemia because no therapy to date can maintain blood glucose within 
the relatively narrow range typical of a normally functioning pancreas [4].   
 Unfortunately, patients with diabetes mellitus must currently manage their 
disease through three to four insulin injections per day.  These injections do not replace 
the normal physiological ability to couple the sensing of blood glucose levels with the 
rapid release of appropriate amounts of insulin [7]. As a result, diabetes patients live with 
an increased risk of life-threatening episodes of hypoglycemia.  In addition, the extreme 
shortage of pancreas donors prevents pancreas tissue transplants from becoming a 
pragmatic solution to diabetes mellitus [7]. Thus, researchers now look to tissue 
engineering solutions to repair the loss of pancreatic physiological function and to 




1.2 Stem cells 
 
Cellular therapy offers a promising new approach for treating disease.  A major 
obstacle, however, in the clinical application of cellular therapy to date is the tremendous 
shortage of needed cells and tissues required for effective human transplantation, 
especially cells that are compatible with the immune system of the patient.  As a result, 
interest has grown in pursuing three major sources of cells – embryonic stem cells, adult 
stem cells, and immortal primary cell lines – as a solution to this shortage in cell supply 
[1, 8-10].  In particular, the isolation of embryonic stem (ES) cells has generated great 
enthusiasm over the potential of producing an unlimited source of transplantable cells, 
due to their capacity to differentiate, as well as their ability to proliferate well in culture.   
Stem cells have the awesome capacity to develop into any adult tissue or to 
continue to undergo self-renewal [11]. The choice between such prolonged self-renewal 
and differentiation is highly regulated by intrinsic signals and the external 
microenvironment.  Stem cells are characterized as either “totipotent,” “pluripotent,” or 
“multipotent” during development. For the first few divisions, the cells of a fertilized egg 
are ‘totipotent’; that is, they are capable of differentiating into all cell types necessary to 
support the development of the organism including both the embryo proper and all extra-
embryonic material.  A few days later, stem cells from the inner cell mass of the 
blastocyst are “pluripotent,” having a more restricted developmental potential and are 
limited to differentiating into all cell types necessary for development of the embryo.  
This developmental potential of stem cells becomes even more restricted later in 
development and throughout the life span of the organism, with adults having a limited 
number of “multipotent” stem cells only capable of differentiating into cells of the organ in 
which they reside, or cell types of a common embryonic origin, a feature referred to as 
plasticity.  Stem cells have been identified in almost all organs within the past 10-20 
years, with hematopoietic stem cells (HSC) the most extensively characterized [12].    
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 Embryonic stem cell research is largely focused on stem cells of human and 
mouse origin, with primate stem cells also receiving ample attention over the last 
decade.  Mouse embryonic stem (mES) cells were first isolated in 1981 by two different 
groups only months apart [13, 14], while isolation of non-human primate embryonic stem 
cells and human embryonic stem (hES) cells occurred more than a decade later.  In 
1995, Jamie Thomson’s group at WiCell Institute in Madison, Wisconsin isolated the first 
primate ES cell line [15]. Just three years later in 1998, Thomson’s group isolated the 
first hES cell line [16]. 
 To date, there are several common features that these ES cells share.  In 
addition to being pluripotent and self-renewing, ES cells express the transcription factor 
Oct-4, which is believed to be an important marker for regulating pluripotency and self-
renewal [17].  Nanog is another transcription factor that is also believed to essential for 
the maintenance of pluripotency and self-renewal [18].  Studies show that these markers 
are expressed exclusively in cells of the ICM, and decreases in expression of either of 
these two key factors correlate with the loss of pluripotency and self-renewal and 
establish the onset of differentiation [19, 20]. 
 Despite these common features of ES cells, there also exist some key 
differences between human and mouse ES cells.  The most significant difference is in 
the dependence of mES cells on the cytokine Leukemia Inhibitory Factor (LIF) for 
maintenance of pluripotency in in vitro culture systems [21].  Human ES cells do not 
show this dependency and appear to not need LIF of either mouse or human origin for 
maintenance of pluripotency [21].  Another key difference between mES cells and hES 
cells is the difference in surface marker expression used for classification of ES cells.  
Mouse ES cells express the surface protein Stage Specific Embryonic Antigen 1 (SSEA-
1) while hES cells are negative for SSEA-1.  Likewise, mES cells are negative for SSEA-
3, SSEA-4, and Tumor Rejection Antigens (Tra) Tra-1-60 and Tra-1-81, while hES cells 
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are positive for all [22].  The expression of these markers is important for classification of 
ES cells and as a measure of pluripotency, as hES cells will loose the expression of 
SSEA-3, SSEA-4, Tra-1-60 and Tra1-81, as well as Oct-4 and Nanog, while gaining the 
expression of SSEA-1, upon differentiation.  Mouse ES cells will also lose expression of 
Oct-4 and Nanog, but will also lose SSEA-1, and have been shown to gain expression of 
SSEA-3 and SSEA-4 upon differentiation [22]. 
Stem cells of the inner cell mass (ICM) of an unmanipulated blastocyst-stage 
embryo will promptly differentiate into primitive ectoderm [23]. This primitive ectoderm 
will ultimately become the three embryonic germ (EG) layers during gastrulation [23].  
Pluripotent mES cell lines are derived from the ICM of a 3.5 day blastocyst [13, 14], 
while hES cells are from a 5-7 day blastocyst [16].  ES cells are isolated from embryos 
grown to the blastocyst stage, and after removal of the trophectoderm, the ICM is 
disaggregated and plated, and outgrowths are selected and expanded [23].  Even when 
removed from their normal embryonic environment, ICM-derived ES cells can proliferate 
and replace themselves indefinitely [23].  If cultured properly in an undifferentiated state, 
ES cells will maintain the developmental potential to form derivatives of all three EG 
layers [23].   
In light of these stem cell properties, ES cells in theory offer a potentially 
unlimited supply of needed cell types and could be engineered into any tissue [2].  
 
1.3 Strategies for creating a transplantable beta cell line from ES cells 
Despite efforts, the generation of functional beta cells from an ES cell source has 
been, for the most part, unsuccessful.  The differences in research geared at deriving 
pancreatic beta cells from mES cells or hES cells has largely been due to ES cell 
availability rather than technical challenges that are unique to one species verses 
another.  The technological hurdles for generating ES cell derived beta cells are similar 
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across both mouse and human ES cells [24].  However, due to the increased knowledge 
and interest in hES cells in the last decade, many research efforts are shifting from 
mouse to human ES cells, and thus it can be expected that the majority of future 
breakthrough’s will undoubtedly occur in hES cell focused research. 
Research with mES cells derived cell types does have a certain advantage over 
studies with their human counterparts.  Mouse ES cells that are of the same lineage as a 
great variety of mouse disease models are readily available [25], which allow the study 
of large populations of subjects of virtually any disease.  In particular, a large variety of 
mouse models is available for various diabetes phenotypes [26-28].  Such availability of 
target disease models makes transplantation studies of engineered mouse cell types to 
evaluate the effectiveness of cellular based therapies for disease less complicated than 
xeno-transplantation studies between mouse models and human cell types.  Due to the 
differences in species, xeno-transplantation treatments pose special concerns such as 
immunorejection that allograft studies do not.  Transplantation of hES cell derived cell 
types into human patients is still years away from clinical investigation, thus these types 
of studies with mouse models provide powerful “proof of principle” data that demonstrate 
the therapeutic potential of ES cell derived cell types, a necessary step to facilitate 
interest in proceeding to non-human primate or human studies.   
Although in theory, ES cells provide an unlimited cell source for the engineering 
of transplantable beta cells, enormous gaps still exist in our knowledge of beta cell 
development from ES cells.  Unlike inducing the erythroid, lymphoid, or neural lineage 
via in vitro differentiation, inducing endoderm-derivatives and insulin-producing cells in 
particular, has proven to be far more difficult.  Thus, efforts to generate functional beta 
cells from well-defined in vitro differentiation protocols have been met with variable 
success.   
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In general, the strategies to induce in vitro pancreatic differentiation of ES cells 
includes engineering ectopic expression of pancreatic master regulatory genes or 
altering the extracellular environment by 1) changing the geometry of the culture 
environment – embryoid body (EB) formation or monolayer culture; 2) providing 
extracellular signals – growth and other factors; 3) nutrient (glucose, amino acids, 
oxygen) restriction or serum reduction; and 4) utilizing extracellular matrix components 
and adhesion molecules (laminins, integrins) [2, 5, 29, 30].  Before tissue engineering 
efforts can differentiate ES cells into pancreatic beta cells in vitro however, the 
processes that regulate pancreas development in vivo must first be understood.   
 
1.4 Pancreas development 
 At around embryonic day 9.5 (E9.5) in the mouse, an evagination on the dorsal 
side of the primitive gut endoderm initiates pancreas development [7, 31-33].  A ventral 
protrusion quickly follows.  Both epithelial buds rapidly grow to form a branched network 
surrounded by mesenchymal tissue [7].  Within the next 10 days, the endocrine, ductal, 
and acinar cells of the pancreas develop [7]. Around E14.5 the definitive pancreas forms 
as the dorsal and ventral lobes fuse together.  From E14 to E18 endocrine cells migrate 
to the mesenchyme from the epithelium to form the islets of Langerhans [7]. These islets 
are composed of four cell types – β cells, which produce insulin; α cells, which produce 
glucagon; δ cells, which produces somatostatin; and PP cells, which produce pancreatic 
polypeptide.  It is not until the end of gestation at about E18.5 that the four islet cell types 
assemble in a specific manner such that β cells form the core surrounded by the other 
cells types [7]. Islet maturation continues even after birth when the ability to regulate 
insulin secretion in response to glucose develops [7].  
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Two phases of transcription factor expression control the development of the 
pancreas.  The first phase plays a prominent role in the growth and differentiation of the 
dorsal and ventral buds protruding from the gut endoderm.  The second phase 
accompanies the formation of the branching epithelial network and leads to endocrine 
and exocrine fate commitments [7, 31-33]. 
 
Transcription factors: general concepts 
Cell differentiation and cell fate determination of stem cells recognizably depend 
on differential gene expression, which causes the increasing divergence of protein 
content in the various cell types formed during development.  Differential gene 
transcription is the greatest contributor to this divergence in cell protein content, and 
achieving it depends significantly on the combination of transcription factors (TFs) the 
cell possesses [8].  Synthesis of TFs and exchange of signals between cells dominate 
the nuclear activity of early embryos, with over half of all genes activated at the onset of 
animal development encoding TFs [3].  Consequently, activation of an increasingly 
complex range of genes ensues to define an organism’s various cell and tissue types [3]. 
 
Currently known transcription factor cascade in endocrine pancreas development 
Transcription factors HNF3, HB9, p48, Brn4, NeuroD1/Beta2, PDX-1, Pax 4, Pax 
6, Isl-1, Nkx2.2, and Nkx6.1, and ngn3 have all been implicated in playing an important 
role in endocrine pancreatic determination and differentiation [3, 34-36].  Among all the 
proendocrine transcription factors, ngn3 and PDX-1 are considered the master 
regulators, whose expression and functions in the developing pancreas have been more 
extensively characterized.   
Ngn3 (neurogenin 3) is a basic helix-loop-helix (bHLH) factor whose expression 
ensues in the second phase of transcription factor cascades in pancreatic development.  
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Ngn3 has a central role in determining the endocrine lineage in the pancreas, defining 
which cells are islet progenitor cells.  Homozygous ngn3 null mutations in mice lead to 
the development of diabetes and their death 1-3 days after birth.  In the ngn3-deficient 
mice, no islets of Langerhans can be found, nor any of the four islet cell types and 
endocrine precursor cells at any stage of development [37-42].   
PDX-1 (pancreatic duodenal homeobox 1) plays an essential role in early 
development during the first phase of transcription factor expression for development of 
the entire pancreas and later on in the second phase for normal beta cell function.  PDX-
1 defines the specific compartment of the endodermal foregut to become the dorsal and 
ventral pancreas, and its absence will result in the arrest of pancreatic morphogenesis 
and differentiation completely.  Later on, PDX-1 is necessary in adult animals to maintain 
beta cell phenotype and to activate the expression of the beta-specific insulin, islet 
amyloid polypeptide (IAPP), GLUT2, and glucokinase (GK) genes [41, 43-49].   
The current model demonstrating the role of the various transcription factors in 
endocrine pancreas differentiation depicts a very simplistic linear cascade for the 
proposed position of each factor (see Figure 1B).  Such delineation, however, does not 
elucidate on their exact mechanism for driving differentiation.  These factors can act at 
several steps or in conjunction with one another.  In this simplified model, many details 
are left out on the specific interaction of transcription factors.  For instance, both 
NeuroD1/Beta2 and Pax4 are direct downstream targets of ngn3, as ngn3 binds to and 
activates their promoters.  In the absence of ngn3, expression of both NeuroD1/Beta2 
and Pax4 is lost.  Further downstream NeuroD1/Beta2 has been shown to interact with 
the E Box regulatory regions of the insulin promoter, while PDX-1 binds to the A Box 
regions [50, 51].  Acting cooperatively, they promote insulin transcription.  Without 
NeuroD1/Beta2 or PDX-1 expression, insulin transcription is severely compromised.   In 
addition, NeuroD1/Beta2 has been shown to form a heterodimer with ubiquitous factor 
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E47 to interact with the E Box domains on the PDX-1 promoter, which are identical to 
the insulin promoter, to upregulate PDX-1 in beta cells [43, 52].  A lack of 
NeuroD1/Beta2 expression correlates to a huge decrease in the number of beta cells.  
Expression of PDX-1 consequently leads to maintenance of beta cell functionality, 
upregulating glucokinase (GK; glycolytic enzyme acting as a glucose sensor for insulin 
secretion), glucose transporter 2 (GLUT2), and prohormone convertase 2 (PC2; enzyme 



































Figure 1.1.  Linear model of transcription factors involved in pancreas development [3, 
29, 54-56]. 
 
1.5 Genetic methods for pancreatic differentiation of ES cells: ectopic expression 
of master transcription factors to generate beta or insulin-producing cells 
 Several studies have already manipulated key transcription factors in the 
endocrine pancreas transcription factor cascade model by overexpressing them in 
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various cell model systems.    Earlier studies have evaluated non stem cell, 
nonendocrine cell models for their ability to transdifferentiate into suitable insulin-
producing cell sources for transplantation upon ectopic expression of transcription 
factors.  Heremans et al. [57] used recombinant adenoviruses to ectopically express 
ngn3 and NeuroD/β2 in adult human pancreatic duct cells.  This ectopic expression 
resulted in Notch ligand, neuroendocrine, and beta cell marker expression.  The number 
of insulin-positive cells increased 15-fold in modified ductal cells over control.  A direct 
correlation between the ectopic expression of ngn3 and the emergence of endocrine 
marker expression existed.  This study also verified that Pax4 and NeuroD1/Beta2 are 
downstream targets of ngn3.  However, the studies conducted by Heremans et al. failed 
to generate cells with a glucose-induced insulin release.  These cells also possessed 
very low cellular insulin content. 
Yoshida et al. stably transfected an intestinal epithelium-derived cell line, IEC-6, 
with PDX1.  For the infected duct cells, gene expression of NeuroD/B2, Pax4, Nkx2.2, 
Pax6, and Nkx6.1 were all induced, as well as a 15-fold increase in insulin-positive cells.  
The transfected IEC-6 cells showed some markers of pancreatic beta cell phenotype 
and were induced to produce insulin upon treatment with betacellulin.  These studies 
demonstrated that overexpression of key transcription factors only leads to partial 
expression of the beta cell phenotype and function in nonendocrine cell types, as the 
cells generated secreted insulin regardless of glucose concentration.   
 Later studies focused on ectopic expression of transcription factors in stem cell 
models.  Blyszczuk et al. [58] coelectroporated R1 mouse ES cells with vectors 
incorporating the mouse PDX-1 and Pax4 genes and cultured them under slightly 
modified Lumelsky et al. differentiation conditions.  They found that ectopic expression of 
Pax4 promoted the differentiation of populations with 60% insulin-producing cells 
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arranged in clusters which released insulin in response to glucose and normalized blood 
glucose levels in streptozotocin-induced diabetic mice.   
Vetere et al. [59] transiently transfected mouse teratocarcinoma F9 embryonic 
stem cells, induced to differentiate with retinoic acid, with an ngn3 expression vector and 
evaluated transcription factor expression in transfected cells.  They established the 
transcription factor sequence Ngn3 → NeuroD → Pax6 → Isl1 by analyzing gene 
expression via quantitative PCR 24, 48, and 72 hours following transfection. 
None of the stem cell studies to date, however, analyze in depth the 
combinational effects of genetic modification and culturing conditions on pancreatic 
differentiation nor analyze in depth the pancreatic transcription factor cascade of 
modified cells.  Blyszczuk et al. looked at mRNA levels of shh, PDX-1, Pax6, IAPP, 
Pax4, isl-1, ngn3, insulin, GLUT2, B-tubulin over 25 days of differentiation, but made no 
analysis of the hierarchy of transcription factors occurring during differentiation nor any 
analysis of a definitive expression pattern necessary to derive insulin-producing cells.  
Even though their cells produced insulin, Blyszczuk et al do not expound upon how the 
insulin content compares to normal islet cells.  Vetere et al. made progressive steps in 
such hierarchy analysis by focusing on expression levels of ngn3, NeuroD, Pax6, and 
Isl1 in transfected F9 cells 24, 48, and 72 hours after transfection or in 10day old EBs.  
However, these findings did not link transcription factor expression to beta physiological 
function, so this hierarchy may not be representative of cells able to produce insulin at a 
physiological level.  Such findings concerned only retinoic acid differentiated cells, and 
not stem cells cultured under established methods of pancreatic islet differentiation.  
Thus room remains for further in depth analysis of the transcription factor hierarchy for 




1.6 Culturing methods for pancreatic differentiation of ES cells 
 
Several major groups have pioneered efforts to differentiate ES cells toward a 
pancreatic fate utilizing sophisticated culturing methods.  Soria et al pioneered efforts to 
differentiate ES cells into the endoderm cell lineage by transfecting mouse ES cells with 
the βgeo gene driven by the human insulin promoter to select for insulin-producing cells 
[30].  Their in vitro differentiation method involves growing ES cells in suspension culture 
(embryoid bodies) in DMEM without LIF and further differentiating the cultures in DMEM 
supplemented with 10mmol/l nicotinamide [30].  Soria et al. were able to obtain an ES-
derived insulin-secreting cell clone with a total insulin content of 16.5 ng/µg protein and 
insulin secreting dynamics somewhat resembling islets [30].  This amount is about 90% 
of a normal mouse islet’s insulin content [30].  Although Soria et al. measured insulin 
release in response to glucose incubation, they did not verify the pancreatic lineage of 
these cells.  They were able to transplant 1x106 insulin positive cells into streptozotocin-
induced diabetic mice.  After transplantation, these mice showed corrected 
hyperglycemia within 1 week, but their condition was completely reversed after 12 weeks 
[30]. 
 Assady et al. went on to demonstrate that embryoid body (EB) formation led to 
the spontaneous differentiation of human ES cells into insulin-producing cells [60].  After 
embryoid body formation, the hES cells were left unpassaged until confluence, and 
replated onto gelatinized six-well tissue culture plates without a feeder layer [60].  A 
growth medium of knockout DMEM supplemented with 20% serum replacement, 1% 
nonessential amino acids, 0.1mmol/l 2-mercaptoethanol, 1mmol/l glutamine, 4ng/mol 
human recombinant basic fibroblast growth factor (bFGF) was used [60].  The cells 
generated by Assady et al. did express some beta cell markers, but they produced 
insulin at very low levels in response to 2 hour glucose incubations, and no quantification 
of the amount of insulin-producing cells produced with this method was determined.   
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 A more complex culturing method for generating islet-like cell types came from 
Lumelsky et al. with their five stage protocol which involved expansion of murine ES 
cells (stage 1), generation of EBs in absence of LIF (stage 2), selecting for nestin-
positive cells in ITSFn medium (stage 3), expanding endocrine progenitors in N2 
medium containing B27 supplement and bFGF (stage 4), and differentiation of islet-like 
clusters by withdrawing bFGF and adding nicotinamide (stage 5) [61] Glucose triggered 
insulin release from these cells demonstrated mechanisms similar to those in vivo, but 
streptozotocin-induced diabetic mice did not display a sustained correction of 
hyperglycemia upon transplantation of cultured ES cell derived insulin positive cells.  
Only 15-31% of cells cultured by this method were insulin-positive, and they contained 
50 times less insulin per cell than normal islet cells [61].  Since then, Hori et al. have built 
on the methods established by Lumelsky et al. by incorporating LY294002, an inhibitor 
of phosphoinositide 3-kinase (PI3K), into stage 5 of the islet differentiation protocol to 
increase total endocrine cell number and insulin content [62]. 
Most recently, Baetge et al. has developed a five stage culture method 
considerably more complex than Lumelsky et al. that differentiated hES cells to produce 
insulin positive cells along with glucagon positive cells, but also produced a population of 
cells that were simultaneously glucagon and insulin positive.  Only 7%-12% of the total 
population was exclusively insulin positive [63].  This same group went on to produce 
pancreatic endoderm progenitors following a modified four stage culture scheme that 
produced cells that were PDX-1 positive but were pre-mature to expressing insulin or 
glucagon.  They then transplanted these PDX-1 positive precursor cells into SCID mice.  
Results showed that these cells went on to develop into mature cells that expressed a 
variety of pancreatic transcription factors such as PDX-1 and Nkx6.1 as well as 
endocrine hormones insulin, glucagon, and ghrelin.  Despite this success, however, 
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some transplanted cells also went on to form teratomas, a consequence that would be 
unacceptable for clinical use in humans [64].   
Although these methods generate insulin positive or islet-like structures from 
both murine and human ES cells by both viral transduction and modified culture 
methods, they fail to generate them at high enough frequency, with high enough insulin 
content, or high enough glucose-responsiveness to merit levels appropriate for clinical 
transplantation.  At least 700-900,000 islets with a normal insulin content of 10µg per 
million cells are needed for transplantation to alleviate type 1 diabetes [61].  The cells 
described above have low insulin content, far below physiologically functional beta cells.  
In addition, the cell lineage of these low insulin-producing cells has not been explored in 
detail to further ascertain their ability to maintain beta cell differentiation long enough to 
be suitable for cellular therapy.  The few studies, such as the ones mentioned above, 
that have explored transplantation of engineered beta-like or insulin positive cell types 
typically show some response to regulating glucose levels in vivo initially, but fail to 
correct the diabetic condition over the long term.  There also remains the serious 
concern over the stability of grafted cells to maintain their beta-like form in a stable state 
without the risk of tumor formation.  Enrichment strategies to increase the yield of 
sustainable beta-functional cells thus need to be greatly improved. 
 
1.7 Gene therapy applications for embryonic stem cells 
By definition, gene therapy is the delivery of genetic material to produce a 
therapeutic effect.  Methods to deliver therapeutic genetic material fall into two broad 
categories: non-viral and viral vectors [65].  Non-viral vectors include liposomes (cationic 
lipids mixed with nucleic acids), nanoparticles, naked DNA delivered by injection or 
electroporation, nanoparticles, or other means [66, 67].  Non-viral vectors still suffer from 
inefficient gene transfer and their expression tends to be transient, preventing their use 
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in many disease applications requiring sustained, high-level expression of the transgene 
[66].  Viral vectors, on the other hand, are derived from viruses with either RNA or DNA 
genomes.  Viral vectors can be either integrating or nonintegrating vectors.  As 
integrating vectors, viral vectors offer the potential for stable, long-term expression of the 
therapeutic gene due to their integration within the target cell genome [66].  In target 
cells where they are maintained as episomes, nonintegrating viral vectors can also offer 
efficient gene transfer [66].   
 Whether by nonviral or viral means, interest has increased in using embryonic 
stem (ES) cells as targets for gene therapy.  Their properties of self-renewal, 
clonogenicity, and pluripotentiality give ES cells the potential to be an unlimited source of 
cells for cell replacement therapy particularly suitable for genetic modification [68, 69].  
Applications of genetically modified ES cells include: 1) studying gene function in stem 
cell biology and development; 2) directing differentiation into specific tissue types; 3) 
selecting and isolating cultures of appropriately differentiating cells for transplantation; 4) 
eliminating contaminating cells in vivo; and 5) developing immunotolerance of 
transplanted cells [68, 69].   
 While clinical application has yet to become a reality, several studies have 
already shown the potential of genetically modified ES cells.  Zandstra et al [70] were 
able to achieve enrichment of cardiomyocytes following genetic modification of mES 
cells with a vector encoding a fusion gene consisting of the alpha-cardiac myosin heavy 
chain (MHC) promoter driving the aminoglycoside phosphotransferase (neomycin 
resistance) gene.  Following the differentiation culture period, treatment with G418 
resulted in cultures composed of more than 70% cardiomyocytes, as verified through 
gene expression, immunohistological and electron microscopic analysis.  In another 
study, Blyszczuk et al. [58] coelectroporated R1 mES cells with vectors incorporating the 
mouse proendocrine  PDX-1 and Pax4 transcription factor genes and cultured them 
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under pancreatic differentiation conditions.  They found that ectopic expression of Pax4 
promoted the differentiation of populations with 60% insulin-producing cells arranged in 
clusters, which released insulin in response to glucose.   When the genetically modified, 
insulin-producing mES cells were transplanted into streptozotocin-induced diabetic mice, 
blood glucose levels normalized.  In a novel approach, Schuldiner et al [71] devised a 
system to remove transplanted, undifferentiated hES cells forming teratomas in mice in 
vivo.  The hES cells were genetically modified prior to transplantation with a vector 
encoding the herpes simplex thymidine kinase (HSV-tk) gene, which is sensitive to the 
FDA-approved drug ganciclovir.  Tumors formed by the transplanted hES cells were 
ablated in mice following administration of ganciclovir, offering an insight to developing a 
safety strategy to eliminate contaminating cells in the host recipient.       
 
1.8 Recombinant retroviruses and lentiviruses as gene transfer vectors  
 In order to express ectopic genes in a target cell, recombinant retroviruses are 
common vehicles for gene transfer, as they accurately and stably integrate the gene of 
interest into the target cell genome and theoretically offer long-term therapy [72, 73].  
Control of long-term expression from retroviral vectors can also be implemented through 
inducible or tissue-specific promoters being included in the vector design [66].  
Frequently used retroviruses for gene transfer are derived from the Moloney murine 
leukemia virus (MLV) or from the human immunodeficiency virus type 1 (HIV-1), a 
member of a more complex subgroup of retroviruses called lentiviruses.   
Recombinant retroviruses are replication-incompetent derivatives of wild-type 
retroviruses.  Wild-type retrovirus particles (Figure 1.2) consist of two identical copies of 
RNA genome surrounded by structural core proteins and encapsidated by a lipid bilayer 
membrane.  From this membrane protrudes multiple knobs of surface envelope proteins.  
The viral RNA consists of three essential genes, gag, pol, and env, which are flanked by 
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long terminal repeats (LTR).  Core structural proteins such as the capsid, matrix and 
nucleocapsid are encoded by the gag gene and are generated by the proteolytic 
cleavage of the gag precursor protein.  Viral enzymes protease, reverse transcriptase, 
and integrase are encoded by the pol gene and are derived from the gag-pol precursor.  
The env gene encodes for the envelope glycoproteins to mediate virus fusion.   
To infect a cell (Figure 1.3), retroviruses attach first to the cell surface through 
nonspecific interactions between surface proteins on the cell and on the virus [74, 75].  
Now at the cell surface, retroviruses bind specifically to their receptor if available to enter 
the cell through membrane fusion.  Following fusion, virus proteins and the virus genome 
are released into the cell.  The viral enzyme reverse transcriptase converts the viral RNA 
into double-stranded proviral DNA.  With its accompanying viral proteins, the proviral 
DNA forms a preintegration complex and translocates to the cell nucleus.  Once inside 
the nucleus, the viral enzyme integrase mediates integration of the provirus into the host 























































Figure 1.3.  Transduction of target cells by recombinant retroviruses.  A virus must 
complete several steps before it successfully inserts the ectopic gene into the genome of 
a target cell.  The virion must first reach the cell surface by convection and/or diffusion 
where it binds nonspecifically and then attaches specifically to the cell surface viral 
receptors.  The virion is subsequently removed from the extracellular environment 
(internalized), sheds its membrane, and releases its internal protein-RNA complex into 
the cytoplasm (un-coats).  The uncoated RNA genome of the retrovirus is then reverse 
transcribed into DNA by reverse transcriptase (a virion associated enzyme) and the 
resultant protein DNA complex (pre-integration complex) is transported to the nucleus 
where it is integrated into the host cell genome by the virion associated enzyme 
integrase.  After integration, the ectopic gene of interest is expressed.    
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 Recombinant retroviruses are identical in structure to wild type virus except they 
carry a genetically engineered genome encoding the gene of interest instead of the viral 
gag, pol, and env structural genes necessary to form an infectious virion capable of 
replicating and producing progeny.  As a result, recombinant retroviruses are incapable 
of self-replication, but still deliver genes in a manner similar to wild type virus [76, 77].  
Recombinant retroviruses, however, retain the regulatory sequences necessary for their 
expression and the special packaging sequence (ψ+) required for their encapsidation into 
an infectious particle [78].  Recombinant retroviruses are generally produced by 
transfecting the producer cell lines with separate expression plasmids encoding the gag, 
pol, and env structural genes (Figure 1.4) and the therapeutic vector with the gene of 
interest.  The subsequently expressed structural gag, pol, and env proteins recognize 
the packaging sequence on the transcribed therapeutic vector and the retroviral and 
lentiviral RNAs are encapsidated into an infectious virion.  These virions are released 
into the culture medium and harvested for future transductions.   
When choosing a retroviral vector for transduction experiments, it is important to 
consider the properties of the target cell.  For instance, recombinant lentiviruses differ 
from basic MLV-derived retroviruses in their ability to infect both dividing and non-
dividing cells, while recombinant retroviruses can only infect actively dividing cells [79, 
80].  This functional difference often makes the use of lentiviruses more advantageous in 
many gene therapy applications [81, 82].  Retroviral vectors have been useful for 
generating stable cell lines expressing a transgene of choice and for marking studies of 
cell lineage.  Dependence on cell division restricts their in vivo applications to gene 
delivery to actively dividing tissues, stem cells and cancer cells.  On the other hand, 
lentiviral vectors can be used for actively dividing cells or direct administration to many 



































Figure 1.4.  Production of recombinant retrovirus stock solutions by producer cell lines.  
Production of recombinant retroviruses involves the transfection of the producer cell line 
with viral vectors encoding the necessary structural and envelope proteins and the 
therapeutic vector containing the gene of interest and the packaging sequence.  The 
therapeutic vector is encapsidated by the proteins encoded on the viral vector and buds 
from the cell to generate the recombinant viral vector.  As the virus buds from the cell 
surface, it incorporates a lipid bilayer from the cell consisting of virus envelope proteins 
and other cell membrane proteins.  Vector particles accumulate in the culture medium 
and are harvested for future use.   
 
 20
The ability of retroviruses and lentiviruses to infect actively dividing cells or 
nondividing cells stems from their routes of entry into the nucleus to integrate their 
genetic material [83, 84].  Because lentiviruses can infect both non-dividing and dividing 
cells, they are presumed to enter the intact nucleus through the nuclear pores [85-88].  
The import of HIV-derived viruses into an intact nucleus remains unclear, but recent 
studies suggest that the HIV preintegration complex (PIC) can bind and use small host 
RNAs (including specific tRNAs or tRNA precursors) as carriers for transport to the 
nucleus [89].  For more simple retroviruses like MLV, successful infection can only occur 
when the cell is actively dividing and the nuclear membrane is dispersed during mitosis 
[90].  Retroviruses become included in the nucleus during the reformation of the nuclear 
membrane in the daughter cells [90].  Otherwise retroviral PICs cannot enter the nucleus 
in cells arrested in G1/G0 or in G2 and remain in the cytoplasm [91, 92].   
Once inside the nucleus, retroviral and lentiviral PICs attack the host 
chromosomal DNA to integrate the viral DNA.  It was previously thought that retroviruses 
and lentiviruses integrated randomly within the host genome [93].  However, recent 
studies have uncovered nonrandom integration patterns [94-98].  MLV-based retroviral 
vectors have been found to integrate predominantly around transcription start sites of 
cellular promoters [99].  In particular, CpG islands, chromosomal regions enriched with 
the CpG dinucleotide, are favorable sites of integration [96].  In contrast, lentiviral 
vectors favor transcription units of active genes and gene-dense regions of the genome 
[96].  These disparate integration patterns of retroviruses and lentiviruses may have 
implications for their safety in human therapies.  Since MLV-based retroviral vectors 
integrate near the 5’ ends of genes, they may be more likely to disrupt transcriptional 
control and expression of potentially oncogenic gene products and lead to the increased 
cancer risks associated with insertional mutagenesis [93, 99].  Insertion of lentiviruses 
within transcription units can lead to frame shifts and other events which interrupt the 
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production of a normal gene product, but lentiviruses may be less likely to induce 
tumorigenesis [93].   Whether lentiviruses offer a safer integrating vector for gene 
therapy, however, needs to be directly demonstrated and confirmed in several animal 
models [93, 99].   
 
1.9 Limitations to retrovirus-mediated gene transfer to embryonic stem cells 
Retrovirus-mediated gene transfer to embryonic stem cells has met with limited 
success, as gene silencing of retroviral vectors has compromised long-term expression.  
Gene silencing is the most widely discussed restriction inhibiting the use of retroviral 
vectors for gene transfer to embryonic stem cells.  Gene silencing is a term used to 
include three related phenomena: 1) transcriptional silencing observed shortly after 
infection; 2) variegation, in which subsets of cells either express or are silent; and 3) 
extinction, whereby long-term culture or differentiation leads to the progressive silencing 
of retrovirus transgenes that were initially expressed [100, 101].   
  The two main molecular mechanisms responsible for gene silencing of 
retroviruses are de novo cytosine methylation and histone remodeling [102].  Methylation 
of DNA involves the addition of a methyl group to the 5’ position of a cytosine in a 
cytosine-phosphate-guanine (CpG) dinucleotide [103].  CpG methylation is catalyzed by 
DNA methyltransferases (DNMTs) and is symmetrical along both DNA strands [103].  
DNMTs can recognize isolated CpGs, clustered CpGs or clustered CpGs within a CpG 
island [103].  Frequency of cytosine greater than 0.6 with a GC dinucleotide content 
greater than 50% defines a CpG island [103].  In particular, DNMTs recognize the CpG 
nucleotides clustered in the U3 region and in the R region directly spanning the 
transcription start site of the long terminal repeat (LTR) promoter of retroviral vectors 
[104].   
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Histone modifications include acetylation, phosphorylation, ubiquitination, and 
methylation [105].  The condensed, inaccessible chromatin marking silenced genes is 
created by histone modifications involving the deacetylation of histones H3 and H4 by 
histone deacetylases HDAC1 and HDAC2 and the abundant presence of linker histone 
H1 [106].   
Silencing of retrovirus transgenes was originally speculated to be due to DNA 
methylation of the CpG islands present in the retroviral LTR promoter.  But more 
recently, two interesting models have emerged to explain retrovirus silencing [102, 107].  
In the first model, DNA methylation has a causal role, whereby methylation acts as a 
genome defense mechanism.  Following methylation of retroviral DNA, the methyl 
groups then become targets for methyl-binding proteins, like MeCP2 [108].  These 
proteins in turn recruit co-repressors such as histone deacetylases, which catalyze the 
deacetylation of histones H3 and H4, leading to chromatin condensation and silencing of 
the retroviral transgene [109].   
In the second model, it is speculated that stem cell-specific factors act as 
negative trans-factors binding to the newly integrated provirus in the negative control 
region (NCR) of retroviral LTR [110].  YY1, ELP, and Factor A have been implicated as 
possible candidates [111-113].  In turn, these negative factors are targeted by histone 
deacetylases, leading to chromatin remodelling and modifications such as acetyl groups 
or methyl groups being attached to histones [102].  This new repressive histone code is 
subsequently targeted by de novo methylase to fully methylate the retroviral LTR.  
Therefore, the role of methylation in this model is to serve as a secondary or associated 
step to maintain and propogate a heritable silenced state.   
With gene silencing as an extremely effective obstacle limiting the use of 
retroviral vectors to genetically modify ES cells, less attention has been paid to other 
possible rate-limiting steps in retrovirus-mediated gene transfer to ES cells.  However, 
 23
multiple steps in the transduction process should be considered when evaluating the 
overall efficiency of gene transfer protocols for stem cells.   
 
1.10 Enhancement of gene transfer using virus-polymer complexation
 Studies have demonstrated that the use of anionic and cationic polymers 
increases the efficiency of retroviral gene transfer.  By combining equal weight 
concentrations of cationic polymer Polybrene (PB) and anionic polymer Chondroitin 
Sulfate C (CSC) to retrovirus stocks, retrovirus-polymer complexes can be formed and 
rapidly pelleted by centrifugation in a table top centrifuge and resuspended in fresh 
culture medium [114].  Due to their large size, the virus-polymer complexes more rapidly 
sediment to the surface of the cells, thus increasing the rate that viruses reach the 
surfaces of cells before they decay and increasing the number of genes transferred 
[115].  Polymer complexation also offers a simplified means of concentrating and 
purifying retrovirus stocks.  Resuspension of the virus-polymer pellet in smaller volumes 
concentrates the virus and has significantly increased the efficiency of gene transfer to 
cell types such as primary human fibroblasts and murine hematopoeitic progenitor cells 
[114-116].  Concentrating the virus by resuspending it in one-eighth its original volume 
can increase gene transfer 10- to 20-fold over original unconcentrated retrovirus stock in 
NIH3T3 murine fibroblasts [114, 115].  Interestingly, the polymer complexes selectively 
integrate more than 70-80% of retrovirus particles and less than 0.3-0.4% of all other 
proteins [114].  These virus-polymer complexes show no detectable levels of inhibitory 
activity due to their purification from inhibitors of transduction like negatively charged 
molecules such as proteoglycans and glycosaminoglycans, as well as free retrovirus 
envelope proteins [117-120].  When virus purified by complexation is used, transduction 
increases monotonically and is linearly proportional to virus concentration in NIH 3T3 
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Figure 1.5.  Procedure for enhancing gene transfer using anionic and cationic polymers. 
 
  
1.11 Thesis objectives 
The long term goal of this thesis was to ectopically express the proendocrine 
transcription factor Neurogenin 3 (ngn3) in murine embryonic stem (mES) cells using 
retroviral gene transfer in order to provide the genetic “push” to regulate their pancreatic 
differentiation and enhance beta cell phenotype expression, thereby improving methods 
to provide a physiologically functional cell source for pancreatic tissue engineering.  
Ngn3 expression in the developing mouse pancreas is essential for endocrine fate 
determination, without which the islets of Langerhans are unable to form.  We 
hypothesized that sustained overexpression of ngn3 in murine embryonic stem cells in 
vitro will be an efficient trigger to enhance the differentiation and beta cell functionality of 
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ES cells, but that multiple steps in the retroviral transduction process restrict the efficient 
expression of such transgenes for therapeutic purposes.   
The objectives of this thesis were to characterize and enhance the efficiency of 
transduction of murine embryonic stem (mES) cells, and to identify any additional 
restrictions to gene transfer in this cell type.  To accomplish these objectives, we 
pursued the following aims: 
1) Evaluate the ability of mES cells to respond to genetic modification with a 
retroviral vector encoding proendocrine transcription factor ngn3.   
2) Determine the extent to which a polymer complexation method to increase 
the rate of transport of viruses to mES cells enhances gene transfer.   
3) Determine the efficiency of major steps in the transduction process in mES 
cells. 
4) Evaluate the effect that a specific genetic mutation in mES cells and chemical 
agent has on gene transfer. 
In these studies, we evaluated gene transfer to ES cells in the mouse model, due 
to the availability of multiple mES cell lines.  In addition, using a mouse model 
afforded us the ability to examine specific gene knockouts, otherwise unavailable in 
other animal or human models.   
 
1.12 Organization of thesis 
In chapter one, we emphasize that the motivation for our work is to derive a 
functional cell source for pancreatic transplantation from embryonic stem cells.  We 
briefly introduce stem cells, gene therapy, the use of recombinant retroviruses as gene 
delivery vectors, and the limitations of employing retroviral-mediated gene transfer to 
embryonic stem cells.   
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In chapter two, we constructed two retroviral vectors encoding proendocrine 
transcription factors Neurogenin 3 (ngn3) and pancreatic duodenal homeobox 1 (PDX-
1).  We then genetically modified mES cells with a retroviral vector encoding 
proendocrine transcription factor ngn3 and examined the resulting pancreatic gene 
expression.   
In chapter three, we evaluate a method for its ability to increase the efficiency of 
retroviral-mediated gene transfer to murine embryonic stem cells by increasing the rate 
and concentration that retroviruses are delivered to the cell surface.  The method 
consists of aggregating retrovirus particles with charged polymers to form high molecular 
weight virus-polymer complexes which rapidly concentrates and purifies virus stocks, as 
well as increases sedimentation of virus particles to the cell surface.  Also, we evaluate 
the utility of pseudotyping retroviruses with various envelope proteins to improve gene 
transfer to embryonic stem cells.   
In chapter four, we examine the efficiency with which embryonic stem cells 
complete the major steps in the retrovirus and lentivirus transduction process in order to 
identify which steps in the virus lifecycle are restricted in mES cells.  Specifically, we 
quantify the rate that viruses attach to and are absorbed by mES cells, integrate, and are 
expressed.   
In chapter five, we examine the efficiency of gene transfer in mES cells using 
three different recombinant viral vectors.  We also evaluate whether nonlethal genetic 
mutations can be made to mES cells to increase the efficiency of gene transfer.   
In chapter six, we summarize our major conclusions and offer suggestions for 
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ECTOPIC EXPRESSION OF PROENDOCRINE TRANSCRIPTION FACTOR 





Complete autoimmune destruction of pancreatic beta cells, where the patient 
exhibits relative or absolute insulin deficiency, characterizes type 1 diabetes, also known 
as insulin-dependent diabetes mellitus (IDDM) [1].  The patient’s pancreatic β-cells can 
no longer produce insulin in response to high blood glucose levels following meals [1].  
Clinical studies suggest, however, that the manifestations of type 1 diabetes could 
potentially be reversed if a renewable source of β-cells or pancreatic islets was available 
for cell replacement therapy [2].  With their capacity for self-renewal and differentiation 
into derivatives of all three germ layers, embryonic stem (ES) cells represent an 
attractive choice for the development of cell therapies for the treatment of diabetes.  In 
order to develop protocols which efficiently differentiate ES cells into pancreas 
progenitor cells or fully differentiated endocrine cell types, understanding the genetic 
networks and extracellular signals involved in endocrine pancreas differentiation is 
essential.   
Several efforts have been made to derive β-cells from ES cells through different 
culturing techniques, but such techniques have been proven unreliable and difficult to 
reproduce [3, 4].  Thus research has refocused on investigating whether the signaling 
pathways of master regulatory genes during embryonic development can be 
recapitulated in ES cells in vitro [5].  A key pancreatic regulatory gene is Neurogenin 3 
(Ngn3), whose expression and functions in the developing pancreas have been more 
extensively characterized.  Ngn3 plays a central role in determining the endocrine 
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lineage in the pancreas, defining which cells are islet progenitor cells.  Homozygous 
ngn3 null mutations in mice result in the complete lack of formation of the islets of 
Langerhans or any of the four islet cell types, leading to the development of diabetes 
and death 1-3 days after birth [6-11].  Direct downstream factors of Ngn3 essential in β-
cell formation are NeuroD1/Beta2 and Pax4, as Ngn3 binds to and activates their 
promoters.  NeuroD1/Beta2 is required for proper morphogenesis of pancreatic islets, 
and Pax4 has been implicated in committing early pancreatic endocrine cells to a β-cell 
fate [12-14].  In the absence of Ngn3, expression of both NeuroD1/Beta2 and Pax4 is 
lost.  Another transcription factor, pancreatic duodenal homeobox 1 (PDX-1), plays a 
prominent role early in the development of the entire pancreas and later on for 
maintaining normal β-cell function and activating β-specific genes [15].  NeuroD1/Beta2 
has been shown to interact cooperatively with PDX-1 to promote insulin transcription in 
β-cells [16, 17].  Without NeuroD1/Beta2 or PDX-1 expression, insulin transcription in β-
cells is severely compromised.    
We hypothesized that sustained ectopic expression of proendocrine transcription 
factor Ngn3 via retroviral genetic modification would be an efficient trigger to enhance 
the expression of downstream regulatory genes in β-cell differentiation.  To evaluate if 
murine ES cells are capable of responding to ectopic expression of Ngn3, we 
constructed an MSCV-derived retroviral vector encoding the expression of Ngn3, 
transduced EFC1 mES cells and a mouse fibroblast cell line as control with Ngn3 
retrovirus, and quantified the resulting gene expression of endocrine pancreas 
transcription factors.   
 
2.2 Materials and Methods 
Chemicals.  Chondroitin sulfate C (CSC) (shark cartilage), gluteraldehyde, 1,5-
dimethyl-1,5-diazaundecamethylene polymethobromide (Polybrene, PB), ANTI-FLAG® 
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M2 monoclonal antibody-Cy3 conjugate and gelatin from porcine skin (Type A) were 
from Sigma Chemical Co. (St. Louis, MO, USA).   
Plasmids.  The expression plasmid encoding the ecotropic (pFBMOSALF) and 
amphotropic (pFB4070ASALF) envelope proteins were from Stephen Russell [18].  The 
expression plasmids encoding proendocrine transcription factors Neurogenin 3 (Ngn3) 
and pancreatic duodenal homeobox 1 (PDX-1) were from David Anderson and Kevin 
Doherty, respectively.  The murine stem cell virus retroviral vector (pMSCV-Gateway-
IRES-eGFP) was from Catherine Verfaillie [19, 20].  
Retroviral vector construction.  The MSCV-FTngn3-eGFP and MSCV-
PDX1cmyc-eGFP retroviral vectors based on the MSCV LTR were constructed, 
according to manufacturer’s instructions, with Gateway® Technology (Invitrogen Corp., 
Carlsbad, CA, USA), which allows DNA segments flanked by a recombination site to be 
transferred into the corresponding site in a Gateway vector.  The entire coding sequence 
of flag-tagged Ngn3 and c-myc-tagged PDX-1 were PCR amplified from their expression 
plasmids and topo cloned into a Gateway® entry vector.  These sequences were then 
transferred via the Invitrogen LR Clonase® reaction to a parent Gateway MSCV 
retrovirus vector (MSCV-Gateway-ires-eGFP), a kind gift from Catherine Verfaillie 
(University of Minnesota).  The final vector sequences were verified by restriction digest 
and DNA sequencing.    
Cell culture.  NIH 3T3 mouse fibroblasts, were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM; Mediatech, Inc., Herndon, VA, USA) with 10% bovine calf 
serum (BCS; Hyclone Labs, Inc., Logan, UT, USA), and 100 U of penicillin and 100 µg of 
streptomycin (Hyclone Labs, Inc., Logan, UT, USA) per mL.  The packaging cell line 
GP2-293 was cultured on collagen-coated plates (BD Biosciences Discovery Labware, 
Bedford, MA, USA) in DMEM (Mediatech, Inc., Herndon, VA, USA) with 10% fetal bovine 
serum (FBS; Hyclone Labs, Inc., Logan, UT, USA) and 100 U of penicillin and 100 µg of 
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streptomycin per mL.  HeLa (human cervical cancer) cells were cultured in DMEM with 
10% FBS and 100 U of penicillin and 100 µg of streptomycin per mL and 110 µg of 
sodium pyruvate (Hyclone Labs, Inc., Logan, UT, USA) per mL.   
Undifferentiated EFC1 mES cells, a kind gift from David Archer (Emory 
University), were cultured on 0.1% porcine gelatin-coated tissue culture flasks and 
plated in ES Complete Medium (ES-DMEM; ATCC, Manassas, VA, USA) supplemented 
with 4mM L-glutamine (Invitrogen Corp., Carlsbad, CA, USA), 150 M β-mercaptoethanol 
(Sigma Chemical Co., St. Louis, MO, USA), 10% heat-inactivated fetal (ES Cell-
Qualified FBS; Invitrogen Corp., Carlsbad, CA, USA), 1% MEM non-essential amino 
acids (Invitrogen Corp., Carlsbad, CA, USA), 100 U of penicillin and 100 µg of 
streptomycin (Invitrogen Corp., Carlsbad, CA, USA) per mL, and 103 U of leukemia 
inhibitory factor (LIF; Chemicon International Inc., Ternecula, CA, USA) per mL.  To 
induce embyroid body (EB) formation, mES cells were plated as 20 µL droplets on the 
cover of nonadherent bacterial culture dishes at a density of 150 cells per µL.  The EBs 
were formed for 6 days in ES Complete Medium without LIF before collection.   
Production of recombinant retroviruses.  To generate retrovirus stocks, GP2-
293 cells, a HEK 293-based packaging cell line that stably expresses the retroviral gag 
and pol genes (Clontech Laboratories, Inc., Mountain View, CA, USA) [21], were plated 
in 10 cm dishes (4x106 cells) in DMEM that contained heat inactivated FBS (10%) but no 
antibiotics.  The next day, Lipofectamine™ 2000 (Invitrogen Corp., Carlsbad, CA, USA), 
was used according to the manufacturer’s recommendations to cotransfect the cells with 
12 µg of a viral envelope expression plasmid (either ecotropic (Eco) or amphotropic 
(Ampho)) and 12 µg of the constructed MSCV-FTngn3 retroviral vector that encoded 
eGFP.  Six hours after transfection, the medium was replaced with fresh 10 mL 
DMEM/FBS with antibiotics.  Virus-laden tissue culture medium was harvested 24, 48, 
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72, and 96 hours post-transfection, filter-sterilized (0.45 µm), and then frozen (-80ºC) for 
later single harvest or combined harvest use.   
  Transduction with polymers.  EFC1 mES and NIH 3T3 cells were plated at 3.5 
x 105 and 1.5 x 105 cells per well, respectively, in gelatinized 6-well tissue culture plates.  
HeLa cells were plated at 5 x 104 cells per well on coverslips in 12-well plates.  The next 
day, equal weight concentrations of 80 µg per mL of cationic polymer Polybrene (PB) 
and anionic polymer chondroitin sulfate C (CSC) were added to ecotropic or 
amphotropic MSCV-FTngn3-eGFP retrovirus stocks and mixed by vortexing.  Virus and 
polymers were incubated together for 20 min, and then centrifuged for 10 min at 10,300 
g at room temperature.  The visible virus-polymer pellets were resuspended in the 
appropriate fresh medium to the desired virus concentration (either in the same volume 
or in one-fifth the volume).  Cells were transduced with 1 mL virus per well, and plates 
were centrifuged for 30 min at 1,100 g at room temperature.  The viral supernatants 
were removed 24 hours later and replaced with fresh medium.  Transduced cells were 
evaluated by fluorescence microscopy, flow cytometry, immunochemistry and real-time 
PCR. 
Fluorescence microscopy.  Three days after transduction, epifluorescent 
images (10X) of EFC1 mES, NIH 3T3 cells and HeLa cells were taken with an inverted 
epifluorescence microscope (IX-50; Olympus America, Inc., Melville, NY, USA).  Images 
represent three independent experiments. 
Flow cytometry.  The percentage of eGFP+ cells and the mean fluorescence 
intensity of eGFP transgene expression in transduced EFC1 mES and NIH 3T3 cells 
was determined 3 days post transduction via flow cytometry using a BD LSR analyzer 
(BD Biosciences, San Jose, CA, USA).  Nontransduced control and MSCV-FTngn3-
eGFP-transduced EFC1 mES and NIH 3T3 cells were trypsinized, pelleted, washed, and 
resuspended in 1X PBS plus 10% FBS to achieve a single-cell suspension.  Ten 
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thousand events were collected per sample.  Nontransduced cells served as negative 
controls and were used to monitor autofluorescence and set fluorescence thresholds.  
Viable cells were gated using forward and side scatter properties. The mean 
fluorescence intensity of eGFP was determined by gating the eGFP+ cells in each 
sample.  Results are representative of three independent experiments.   
Immunofluorescence Microscopy.  To determine if transduction with MSCV-
FTngn3-eGFP lead to stable integration of the FTngn3 sequence and translation of the 
FTngn3 protein, HeLa cells were immunostained by plating them on coverslips (no. 1.5 
12mm, Fisher Scientific; Suwanee, GA, USA) in 12-well plates (50,000 cells per well).  
Three days after transduction, the cells were fixed with 2% paraformaldehyde (1 
mL/well) for 10 min.  Next the cells were washed 3 times with PBS and incubated with 
ANTI-FLAG® M2 monoclonal antibody-Cy3 conjugate (diluted 800-fold in Tris Buffered 
Saline (TBS), 0.05 M Tris, pH 7.4, with 0.15 M NaCl) for 1 hour at room temperature, 
washed 3 times with PBS and once with double distilled water, and then their nuclei 
were stained with DAPI (300nM in PBS) for 1 min at room temperature.  The cells were 
subsequently washed with double distilled water (1 mL/well), and the coverslips were 
mounted on glass slides with gelvatol [22].  All cells were examined by epifluorescence 
microscopy (IX-50; Olympus America, Inc., Melville, NY, USA; 60 X oil objective). 
Determination of proendocrine transcription factor and reporter gene 
mRNA expression by real-time PCR.  Extraction of total RNA from cell cultures was 
performed using RNeasy® Mini Kit and QIAamp® Columns (Qiagen Inc., Valencia, CA, 
USA).  DNase treatment of RNA was performed on-column using RNase-free DNase Kit 
(Qiagen Inc., Valencia, CA, USA).  Reverse transcription of RNA into cDNA was 
performed using 3 µg of total RNA in a final volume of 20 µL, using oligo dT primers and 
SuperScriptTM III First-Strand Synthesis System for RT-PCR (Invitrogen Corp., Carlsbad, 
CA, USA).  Ngn3, NeuroD1, Pax4, Dll-1, and PDX-1 transcription factors, eGFP 
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(reporter) and 18SrRNA (endogenous reference) gene-specific primer pair sequences 
(Applied Biosystems, Foster City, CA, USA or Integrated DNA Technologies, Inc., 
Coralville, IA, USA) were as follows:  Ngn3 forward primer 5’-
GCGCAAGAAGGCCAATGA-3’ and Ngn3 reverse primer 5’-
AGCGCCGAGTTGAGGTTG-3’; NeuroD1 forward primer 5’-ACCAATTTGGTCGCCGG-
3’ and NeuroD1 reverse primer 5’-GGGTTCTGCTCAGGCAAGAA-3’; Pax4 forward 
primer 5’-GGGACTGCCAATCCCTCC-3’ and Pax4 reverse primer 5’-
GGCAGGGCCAGGCAA-3’; Dll-1 forward primer 5’-TACCCCTAACCCATGCGAGA-3’ 
and Dll-1 reverse primer 5’-GGCAACGGAAGTCACCCC-3’; PDX-1 forward primer 5’-
AAATCCACCAAAGCTCACGC-3’ and PDX-1 reverse primer 5’-
CTCGGGTTCCGCTGTGTAAG-3’; eGFP forward primer 5’-
AGCAAAGACCCCAACGAGAA-3’ and eGFP reverse primer 5’-
GGCGGCGGTCACGAA-3’;  and 18SrRNA forward primer 5’-
CGCCGCTAGAGGTGAAATTC-3’ and 18SrRNA reverse primer 5’-
TTGGCAAATGCTTTCGCTC-3’.  Standards for eGFP, Ngn3, and 18SrRNA were 
prepared from amplifications purified using an E.Z.N.A® Gel Extraction Kit (Omega Bio-
tek, Inc., Doraville, GA, USA) and serially diluted.  All real-time PCR reactions were 
performed by amplifying 1 µL of cDNA in a 30 µL total volume with SYBR® Green PCR 
Master Mix (Applied Biosystems, Inc., Foster City, CA, USA) in an ABI PRISMTM 7700 
Sequence Detector (2 min at 50ºC, 10 min at 95ºC, and then 40 cycles of 15 sec at 95°C 
and 1 min at 60°C) [23-28].  Detection limits for each gene were determined by no 
template control.  The relative standard curve method, as described in ABI User Bulletin 
#2 Rev B: ABI Prism 7700 Sequence Detection System [29], was used to quantify the 
level of mRNA expression of eGFP in EFC1 mES cells, and the results were expressed 
as relative to the expression levels of endogenous 18SrRNA, the reference gene.  
Quantification of mRNA gene expression of transcription factors Ngn3, NeuroD1, Pax4, 
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Dll-1, and PDX-1 in EFC1 mES cells  was based on the comparative CT method for each 
sample, as described in ABI User Bulletin #2 Rev B: ABI Prism 7700 Sequence 
Detection System [29], and expressed as relative expression normalized to the 
18SrRNA endogenous reference gene and depicted as an n-fold difference relative to 
nontransduced cells.  Values are the mean ± the standard deviation for triplicate 
samples. 
Data analysis.  Data are summarized as the mean ± the standard deviation for 
at least triplicate samples.  Statistical analysis was performed with MINITAB® Release 
12.23 software (Minitab, Inc., State College, PA, USA) using a one-way analysis of 
variance (ANOVA) for repeated measurements of the same variable.  The Tukey 
multiple comparison test was used to conduct pair wise comparisons between means. 
Differences at p < 0.05 were considered statistically significant.   
 
2.3 Results 
Technologies are in great demand to efficiently generate insulin-producing β-like 
cells in sufficient quantities for the treatment of type 1 diabetes.  As most culturing 
methods alone are not adequate to generate β-cells, we speculated that ectopic 
expression of key proendocrine transcription factors, Neurogenin 3 (Ngn3) in particular, 
would be a more efficient trigger than culturing methods for initiating the subsequent 
signal cascades that lead to pancreatic β-cell formation.   
In order to assess the ability of murine embryonic stem (ES) cells to respond to 
ectopic expression of proendocrine transcription factor Neurogenin 3 (Ngn3), we 
constructed two murine stem cell virus (MSCV) retroviral vectors encoding for 
proendocrine transcription factors Neurogenin 3 (Ngn3) and pancreatic duodenal 






















Figure 2.1.  Schematic diagram of the two MSCV retroviral vectors constructed, 
containing the MSCV long terminal repeat (LTR) promoter followed by a packaging 
sequence (Ψ+).  One vector encodes for the flag-tagged proendocrine transcription 
factor Neurogenin 3 (FTngn3), the other for the cmyc-tagged pancreatic duodenal 
homeobox-1 (PDX-1-cmyc).  The enhanced green fluorescent protein (eGFP) is 
downstream of an internal ribosome entry site (IRES).   
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 To examine the effect of ectopic expression of Ngn 3 in mES cells, we first 
generated stocks of ecotropic MSCV-FTngn3-eGFP virus by transfecting GP2 packaging 
cells that stably express the gag and pol genes and evaluated the efficiency of gene 
transfer.  EFC1 mES cells and NIH 3T3 cells were transduced with ecotropic MSCV-
FTngn3-eGFP retrovirus that had been precipitated with 80 µg/mL each of Polybrene 
(PB) and chondroitin sulfate C (CSC) and resuspended in the same volume.  Three days 
later we visualized the cells by epifluorescence microscopy (Figure 2.2A and 2.2B), used 
flow cytometry to quantify the number of transduced cells (Figure 2.2C and 2.2D), and 
used real-time PCR to quantify the level of eGFP mRNA.   
We found that our MSCV-FTngn3-eGFP virus successfully transduced both 
EFC1 mES cells and NIH 3T3 cells, as demonstrated by the presence of eGFP+ cells in 
transduced cultures (Figure 2.2A and 2.2B).  However, the number of transduced NIH 
3T3 cells was significantly higher than the number of transduced EFC1 mES cells 
(Figure 2.2C and 2.2D).  Typically, NIH 3T3 cells showed transduction efficiencies of 70-
80%, while the highest transduction efficiencies achieved in EFC1 mES cells were 3-4%.  
In addition, eGFP expression in individual transduced NIH 3T3 cells was much higher 
than in individual transduced EFC1 mES cells (Figure 2.2A and Figure 2.2B).  We 
conducted real-time PCR to quantify the level of eGFP mRNA in transduced cultures.  
We found that transduced EFC1 mES cells expressed significantly lower levels of eGFP 













Figure 2.2.  Expression of eGFP can be detected in EFC1 mES cells and NIH 3T3 cells.   
Fluorescent images detecting eGFP expression in EFC1 mES cells (A) and NIH3T3 cells 
(B) that were seeded in gelatinized 6-well plates at 3.5 x 105 and 1.5 x 105, respectively, 
and transduced the next day with ecotropic MSCV-FTngn3-eGFP virus precipitated with 
polymers and resuspended in the same volume.  Three days later the cells were 
visualized by epifluorescence (A, B), the number of transduced cells determined by flow 
cytometry (C, D), and the levels of eGFP mRNA quantified by real-time PCR (E).  Flow 
cytometry histograms of non transduced control (black) and transduced (red) NIH 3T3 
cells (C) and EFC1 mES cells (D).  Statistically significant difference (p<0.05) in the level 

















































A HeLa human cervical carcinoma cell line was next examined to verify that 
transduction with MSCV-FTngn3-eGFP virus leads to stable integration of the FTngn3 
sequence within the host genome and to translation of an FTngn3 protein.  HeLa cells 
were transduced with 5-fold polymer concentrated amphotropic MSCV-FTngn3-eGFP 
virus (Figure 2.3H).  Three days post transduction, immunoreactivity of an ANTI-FLAG® 
M2 monoclonal antibody-Cy3 conjugate to the flag tag fusion protein (FT) of the 
exogenous FTngn3 was used to detect cells making functional FTngn3 protein.  HeLa 
cells stained positive for the FTngn3 protein in eGFP+ cells (Figure 2.3 A and 2.3B), 
demonstrating translation of the FTngn3 protein in transduced cells.  Staining of cell 
nuclei (Figure 2.3C) also revealed that FTngn3 protein expression in HeLa cells was 




Figure 2.3.  Transduced eGFP+ HeLa cells stain positive for FTngn3 protein expression.   
Fluorescent image detecting eGFP expression in transduced HeLa cells incubated with 
antibody (A, H) and nontreated control (E).  Immunofluorescence staining for flag tag 
fusion protein in transduced HeLa cells incubated with antibody (B) and nontreated 
control (F).  DAPI staining of nuclei (C, G).  Overlay (D) of (B) and (C) to show 




As a first step towards analyzing the effect of ngn3 expression on mES cell fate, 
we transduced EFC1 mES cells, and NIH 3T3 murine fibroblasts as a control, with 
ecotropic MSCV-FTngn3-GFP virus, then quantified the level of expression of Ngn3 by 
real-time PCR 3 and 5 days following transduction (Figure 2.4).  Ngn3 expression was 
detected at high levels in transduced NIH3T3 cells 3 and 5 days after transduction.  
However, Ngn3 expression in transduced mES cells was about 700-fold lower at day 3 








































Figure 2.4.  Expression of the Ngn3 transgene is signicantly lower in transduced EFC1 
mES cells than in NIH 3T3 cells.  EFC1 mES and NIH 3T3 cells were plated (350,000 
cells/well and 150,000 cells/well, respectively) in gelatinized 6-well tissue culture plates, 
and then transduced the next day with ecotropic MSCV-FTngn3-eGFP virus precipitated 
with polymers and resuspended in the same volume.  Three and five days later, total 
RNA was extracted from the lysates of EFC1 mES (white bars) and NIH 3T3 (black bars) 
cells and reverse transcribed using oligo dT primers, and the relative amount of cDNA 
was quantified by real-time PCR and is reported as n-fold differences relative to cells 
that were not transduced.  Each bar represents the mean ± standard deviation of three 
replicates.  Statistically significant (p<0.05) differences of Ngn3 expression levels in 
EFC1 mES cells from NIH 3T3 cells are denoted with an asterisk (*).    
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To next determine if mES cells were competent to respond to ectopic expression 
of Ngn3 and regulate additional factors in the proendocrine transcription factor cascade, 
we transduced EFC1 mES cells and NIH 3T3 cells with ecotropic MSCV-FTngn3-GFP 
virus, and then used real-time PCR to quantify the level of expression of Ngn3, as well 
as NeuroD1, Pax-4, Dll-1, and PDX-1, transcription factors whose in vivo expression is 
regulated by Ngn3 (Figure 2.5).  Ngn3 expression was significantly higher in transduced 
cells than in nontransduced cells for both 3 and 5 days post transduction (Figure 2.5).  
Ngn3 expression in transduced EFC1 mES cells was 3-fold higher than nontransduced 
cells at 3 days post transduction and 6-fold higher at 5 days post transduction (p<0.05).  
For NeuroD1, Pax-4, Dll-1, and PDX-1, gene expression was about 2-fold higher in the 
transduced cells than in the non transduced cells (Figure 2.5) by 5 days post 
transduction (p<0.05).  These results suggest that the product of the FTngn3 transgene 
may upregulate the expression of transcription factors in mES cells that it is known to 
regulate in development in vivo.  Levels of expression of NeuroD1, Pax-4, Dll-1, and 
PDX-1 did not increase when, as a negative control, NIH 3T3 murine fibroblasts were 
transduced to express Ngn3 (data not shown).   
 Next, we wondered if expression of proendocrine factors could be maintained 
during continued culture and into differentiation.  We transduced EFC1 mES cells with 
ecotropic MSCV-FTngn3-eGFP virus, cultured them for 16 days in monolayer and then 
iniated differentiation by embryoid body (EB) formation, with nontransduced control mES 
cells cultured in parallel.  We used real-time PCR to quantify the level of expression of 
Ngn3, NeuroD1, Pax-4 and PDX-1 following EB formation (Figure 2.6) as compared to 
two days post transduction.  We found that expression of Ngn3 significantly decreased 
by about 30-fold (p<0.05) after EB formation in comparison to 2 days post transduction.  

















































Figure 2.5.  Transduction of EFC1 mES cells with MSCV-FTngn3-eGFP leads to 
increased expression of Ngn3 and its downstream factors.  EFC1 mES cells were plated 
(350,000 cells/well) in gelatinized 6-well tissue culture plates, and then transduced the 
next day with ecotropic MSCV-FTngn3-eGFP virus precipitated with polymers and 
resuspended in the same volume.  Three and five days later, total RNA was extracted 
from the lysates of EFC1 mES cells and reverse transcribed using oligo dT primers, and 
the relative amount of cDNA was quantified by real-time PCR and is reported as n-fold 
differences relative to cells that were not transduced.  Each bar represents the mean ± 
standard deviation of three replicates.  Statistically significant (p<0.05) differences of 
transcription factor expression levels in transduced EFC1 mES cells from nontransduced 


































Figure 2.6.  Following embryoid body (EB) formation, expression of Ngn3 is sigficantly 
lower than 2 days post transduction of EFC1 mES cells.  .  EFC1 mES cells were plated 
(350,000 cells/well) in gelatinized 6-well tissue culture plates, and then transduced the 
next day with ecotropic MSCV-FTngn3-eGFP virus precipitated with polymers and 
resuspended in the same volume.  Three and five days later, total RNA was extracted 
from the lysates of EFC1 mES cells and reverse transcribed using oligo dT primers, and 
the relative amount of cDNA was quantified by real-time PCR and is reported as n-fold 
differences relative to cells that were not transduced.  Each bar represents the mean ± 
standard deviation of three replicates.  Statistically significant (p<0.05) differences of 
transcription factor expression levels in transduced EFC1 mES cells from nontransduced 





In order to determine the effect of ectopic expression of Ngn3 in murine ES cells 
we employed retroviruses as our gene delivery vehicle.  We constructed two MSCV-
derived retroviral vectors encoding for proendocrine transcription factors Ngn3 and PDX-
1.  We genetically modified mES cells with our Ngn3 retrovirus to ectopically express 
Ngn3, and we found its overexpression was followed by a 2-fold upregulation at 5 days 
post transduction of NeuroD1/Beta2, Pax4, Dll-1, and PDX-1, other important 
proendocrine transcription factors whose expression is regulated by or downstream of 
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Ngn3.  These results suggest that pluripotent mES cells may be competent to respond to 
Ngn3 and support our hypothesis that ectopic expression of these factors can be used to 
induce mES cells to adopt an endocrine fate.  However, following long-term culture and 
embryoid body differentiation, expression of most proendocrine transcription factors 
decreased.  In addition, our retrovirus transduction methods were inefficient for gene 
transfer to mES cells, demonstrated by low transgene expression levels of both Ngn3 
and the eGFP reporter gene in EFC1 mES cells in comparison to NIH 3T3 fibroblasts, an 
easy to transduce cell type.   
We found our observation that retroviral transgenes were expressed at a very 
low level in EFC1 mES cells in comparison to NIH 3T3 expression levels rather 
surprising, considering that the retroviral vectors we constructed were based on the 
state- of- the- art murine embryonic stem cell virus (MSCV).  MSCV vectors contain CpG 
mutations in their long terminal repeats (LTR) designed to eliminate cis-acting repressor 
elements that serve as binding sites for methyltransferases that, when bound to 
retroviral DNA, methylate it and silence its [30].  Considering the degree of transgene 
silencing observed, it will be necessary to develop more efficient methods for genetically 
modifying mES cells with retroviruses.   
After transducing EFC1 mES cells with our retroviruses encoding Ngn3, we 
evaluated the gene expression of the entire transduced culture which included a mixed 
population of successfully transduced and nontransduced EFC1 mES cells.  Considering 
retroviral transgene silencing and mixed populations of transduced and nontransduced 
cells, the resulting effects of ectopic Ngn3 expression may not be as pronounced.  
Future work regarding overexpression of Ngn3 and evaluating its effects in ES cells 
should include isolating only successfully transduced cells by fluorescent activated cell 
sorting (FACS).   
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Another point of interest for future studies is the temporal effects of ectopic 
expression of master proendocrine transcription factors.  For these studies we only 
evaluated the effects on ectopic expression on Ngn3 although we constructed two 
retroviral vectors encoding both Ngn3 and PDX-1.  Further studies should perhaps 
include transduction of ES cells with both retroviral vectors for a combined effect or 
transduction with first one and then the other vector at different time points to better 
determine how to manipulate overexpression of proendocrine transcription factors to 
more naturally recapitulate their expression patterns during differentiation in vivo.  Other 
efforts could be spent examining overexpression of Ngn3 from an inducible system in 
the event that constitutive overexpression appears undesireable.   
Interestingly we observed that expression of almost all transcription factors 
(except Pax4) decreased following continued culture and initiation of differentiation 
through EB formation.  This decrease could possibly be due to the further silencing of 
the Ngn3 transgene upon ES cell differentiation, which has been observed when using 
retroviral vectors.  This decrease could also be due to the choice of culture condition.  
EB formation may be counteractive to any pancreatic transcription factor cascades 
possibly initiated.  Investigating culture conditions for differentiating ES cells that are 
complimentary to overexpression of proendocrine factors may warrant further effort.   
 In summar, we focused on pancreatic gene expression following ectopic Ngn3 
expression.  To further characterize how genetic modification of ES cells influences their 
cell fate decisions, ES cells should be immunostained for pancreatic-specific markers 
including insulin (beta cells), glucagon (alpha cells), somatostatin (delta cells), and 
pancreatic polypeptide (PP cells).  The level of beta cell physiological function should 
also be assessed determining the total insulin content of the cells, and the amount of 
insulin secreted in response to perturbations in the extracellular concentrations of 
glucose by cells precultured in regular or insulin-free medium in the presence or 
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absence of agonists (tolbutamide, IBMX, and carbachol) and antagonists (diazoxide and 
nifedipine) of insulin secretion.  Such work would improve our knowledge to establish 
improved methods to produce cells in greater quantities that more closely resemble 
mature β-cells in physiological function.   
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COMPLEXATION OF RETROVIRUSES WITH POLYMERS SIGNIFICANTLY 
INCREASES THE NUMBER OF GENES TRANSFERRED TO MURINE EMBRYONIC 





Embryonic stem (ES) cells hold great promise for use in regenerative medicine 
and in the treatment of disease because of their capacity to self-renew, and their 
potential, when provided with appropriate cues, to differentiate into all cell types of the 
body.  To help realize the full potential of ES cells, it is essential that an effective means 
to genetically modify them is developed.  Genetic modification of ES cells can be used to 
explore basic questions in stem cell biology and development, to track or direct their 
differentiation, to develop strategies to down-regulate their immunogenicity, and to 
create cellular therapies for the treatment of disease [1-3].  Recombinant retroviruses 
derived from the Moloney murine leukemia virus (MoMLV) are one of the most effective 
means for genetically modifying most cell types because they efficiently and 
permanently integrate their genetic material into the chromosomal DNA of the cells, 
which gives rise to high levels of sustained expression of the integrated transgene in the 
transduced cells and their progeny [4].  Unfortunately, MoMLV-derived retroviruses have 
proven less useful for the genetic modification of ES cells because ES cells employ 
multiple mechanisms to partially or completely silence their expression [5].  To overcome 
this limitation, retrovirus vectors have been developed that are less susceptible to 
silencing.  For example, retroviruses derived from the murine stem cell virus (MSCV) 
contain CpG mutations in their long terminal repeats (LTR).  These mutations eliminate 
cis-acting repressor elements that serve as binding sites for methyltransferases that, 
                                                 
1 Modified from Biotechnology and Applied Biochemistry, 2008 Feb 11 (Epub ahead of print) 
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when bound to retroviral DNA, methylate it and silence its expression [5-11].  Despite 
these improvements in vector design, expression from integrated retrovirus transgenes 
is still low and variable in ES cells [12, 13].   
Most efforts to solve this problem continue to focus on increasing the resistance 
of retrovirus vectors to ES cell silencing mechanisms [9, 14].  As an alternative 
approach, we wondered to what extent retrovirus transgene expression could be 
improved by increasing the number of transgenes that are integrated into the 
chromosomal DNA of ES cells.  To evaluate the effectiveness of this approach, we first 
developed a method to substantially increase the efficiency of retrovirus gene transfer to 
ES cells.  To accomplish this, we identified which of four commonly used retrovirus 
pseudotypes transduce ES cells most efficiently and then rapidly delivered high doses of 
that virus to ES cells as a complex with the cationic polymer Polybrene (PB) and the 
anionic polymer chondroitin sulfate C (CSC).  We have previously shown that retrovirus-
polymer complexes transfer genes to cells more efficiently than neat retrovirus stocks 
because they contain fewer inhibitory substances, can be suspended in culture medium 
that is optimized for the cell type being transduced, and rapidly deliver large numbers of 
active retroviruses to the surfaces of the cells being transduced [15-18].  Using this 
method for transducing ES cells, we significantly increased the level of gene transfer to 
D3 and R1 murine embryonic stem cells, and to NIH 3T3 murine fibroblasts as a control, 
and then quantitatively examined the relationship between the number of integrated 
transgenes per cell and the overall level to which the integrated transgenes were 
expressed. 
 
3.2 Materials And Methods 
Chemicals.  Chondroitin sulfate C (CSC) (shark cartilage), gluteraldehyde, 1,5-
dimethyl-1,5-diazaundecamethylene polymethobromide (Polybrene, PB), Alkaline 
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Phosphatase Yellow (pNPP) Liquid Substrate System for ELISA (p-nitrophenyl 
phosphate), alkaline phosphatase from bovine intestinal mucosa (Type VII-S), 1-(4,5-
Dimethylthiazol-2-yl)-3,5-diphenylformazan (MTT) and gelatin from porcine skin (Type A) 
were from Sigma Chemical Co. (St. Louis, MO, USA).  Hydrogen peroxide 30%, bovine 
serum albumin fraction V (BSA), polyoxyethylene 20-sorbitan monolaurate (Tween 20), 
Triton-X and sodium dodecyl sulfate (SDS) were from Fisher Scientific (Pittsburg, PA, 
USA).  Non-fat dry milk (blotting grade) was from Bio-Rad Laboratories (Hercules, CA, 
USA).  Mouse anti-p30 antibody was purified from the supernatant of the CRL-1219 
(ATCC, Rockville, MD, USA) hybridoma cell line, following standard procedures [19].  
The goat polyclonal anti-p30 antibody (78S221) was from Quality Biotech (Camden, NJ, 
USA).  The horseradish peroxidase conjugated rabbit anti-goat immunoglobulin G 
polyclonal antibody was from Zymed Laboratories (South San Francisco, CA).   
Plasmids.  The expression plasmids encoding the ecotropic (pFBMOSALF) and 
amphotropic (pFB4070ASALF) envelope proteins were from Stephen Russell [20].  The 
expression plasmids encoding the 10A1 (pIK.MCV.10A1.env.uTd) [21], and VSV-G 
(pMD.G) [22, 23] envelope proteins were from Maribeth Eiden and Scott Case, 
respectively.  The murine stem cell virus retroviral vector (pMSCV-IRES-eGFP) was 
from Catherine Verfaillie [24, 25].  
Cell culture.  NIH 3T3 mouse fibroblasts, were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM; Mediatech, Inc., Herndon, VA, USA) with 10% bovine calf 
serum (BCS; Hyclone Labs, Inc., Logan, UT, USA), and 100 U of penicillin and 100 µg of 
streptomycin (Hyclone Labs, Inc., Logan, UT, USA) per mL.  The packaging cell line 
GP2-293 was cultured on collagen-coated plates (BD Biosciences Discovery Labware, 
Bedford, MA, USA) in DMEM (Mediatech, Inc., Herndon, VA, USA) with 10% fetal bovine 
serum (FBS; Hyclone Labs, Inc., Logan, UT, USA) and 100 U of penicillin and 100 µg of 
streptomycin per mL.  Undifferentiated D3 murine embryonic stem (mES) cells, obtained 
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from ATCC, and undifferentiated R1 mES cells, a kind gift from Todd McDevitt (Georgia 
Tech), were cultured on 0.1% porcine gelatin-coated tissue culture flasks and plated in 
ES Complete Medium (ES-DMEM; ATCC, Manassas, VA, USA) supplemented with 
4mM L-glutamine (Invitrogen Corp., Carlsbad, CA, USA), 150 M β-mercaptoethanol 
(Sigma Chemical Co., St. Louis, MO, USA), 10% heat-inactivated fetal (ES Cell-
Qualified FBS; Invitrogen Corp., Carlsbad, CA, USA), 1% MEM non-essential amino 
acids (Invitrogen Corp., Carlsbad, CA, USA), 100 U of penicillin and 100 µg of 
streptomycin (Invitrogen Corp., Carlsbad, CA, USA) per mL, and 103 U of leukemia 
inhibitory factor (LIF; Chemicon International Inc., Ternecula, CA, USA) per mL.   
Production of recombinant retroviruses.  To generate retrovirus stocks, GP2-
293 cells, a HEK 293-based packaging cell line that stably expresses the retroviral gag 
and pol genes (Clontech Laboratories, Inc., Mountain View, CA, USA) [26], were plated 
in 10 cm dishes (4x106 cells) or T175 flasks (12.5x106 cells) in DMEM that contained 
heat inactivated FBS (10%) but no antibiotics.  The next day, Lipofectamine™ 2000 
(Invitrogen Corp., Carlsbad, CA, USA), was usesd according to the manufacturer’s 
recommendations to transfect the cells with one of the expression plasmids (12 µg in 10 
cm dishes or 38 µg in T175 flasks) for the following viral envelope proteins: ecotropic 
(Eco), amphotropic (Ampho), 10A1, or VSV-G, and a MSCV-derived retroviral vector that 
encoded eGFP (12 µg in 10 cm dishes or 38 µg in T175 flasks).  Six hours after 
transfection, the medium was replaced with fresh 10 mL or 40 mL DMEM/FBS with 
antibiotics.  Virus-laden tissue culture medium was harvested 24, 48, 72, and 96 hours 
post-transfection, filter-sterilized (0.45 µm), and then frozen (-80ºC) for later single 
harvest or combined harvest use.  The concentration of virus capsid protein (p30) in the 
virus stocks was determined using a previously described enzyme-linked 
immunosorbent assay (ELISA) [15].    
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  Diluted titer assay.  To determine virus titer, ten-fold serial dilutions of MSCV-
eGFP virus stock (from 48 hr harvests) were made in ES Complete Medium and 
Polybrene (8µg per mL).  Serially diluted virus (1 mL per dish) was used to transduce D3 
and R1 mES and NIH 3T3 cells that had been seeded at 3.5 x 105 and 1.5 x 105 cells 
per dish, respectively, in 35 mm gridded (2 mm) dishes (Nalge Nunc International, 
Rochester, NY, USA).  The viral supernatants were removed 24 hours later and replaced 
with fresh medium.  Three days post transduction, the number of clusters of eGFP+ 
mES and NIH 3T3 cells (typically in clusters of 2, 4, 8, or 16 green cells) were counted 
with the aid of an inverted epifluorescence microscope (IX-50; Olympus America, Inc., 
Melville, NY, USA), and multiplied by the dilution factor to determine the titer (i.e., the 
number of eGFP+ colony forming units (CFU) per mL).  Typical titers measured with NIH 
3T3 cells were 1.2 ± 0.17 x 105 (amphotropic), 6.9 ± 0.73 x 105 (ecotropic), 1.0 ± 0.12 x 
105 (10A1), and 7.1 ± 0.15 x 105 CFU/mL (VSV-G) CFU/mL.  Results are representative 
of three independent experiments. 
Determination of viral receptor and pluripotency marker mRNA expression 
by real-time PCR.  Extraction of total RNA from cell cultures was performed using 
RNeasy® Mini Kit and QIAamp® Columns (Qiagen Inc., Valencia, CA, USA).  DNase 
treatment of RNA was performed on-column using RNase-free DNase Kit (Qiagen Inc., 
Valencia, CA, USA).  Reverse transcription of RNA into cDNA was performed using 3 µg 
of total RNA in a final volume of 20 µL, using oligo dT primers and SuperScriptTM III First-
Strand Synthesis System for RT-PCR (Invitrogen Corp., Carlsbad, CA, USA).  MCAT-1 
(ecotropic receptor), Pit-2 (amphotropic receptor), Oct-4 (mES pluripotency marker), 
Nanog (mES pluripotency marker) and GAPDH (endogenous reference) gene-specific 
primer pair sequences (Integrated DNA Technologies, Inc., Coralville, IA, USA) were as 
follows:  MCAT-1 forward primer 5’-TGCCATCGTCATCTCCTTCTT-3’ and MCAT-1 
reverse primer 5’-CGTAGCACAGGCCGGC-3’; Pit-2 forward primer 5’-
 68
CTTTCAGAGCCTCGGACACC-3’ and Pit-2 reverse primer 5’-
CACACTGTCACCCACCAGCT-3’; Oct-4 forward primer 5’-
CCAGGCTCAGAGGTATTGGG-3’ and Oct-4 reverse primer 5’-
ATCCCTCCGCAGAACTCGTA-3’; Nanog forward primer 5’-
GCATCCATTGCAGCTATCCC-3’ and Nanog reverse primer 5’-
GCCCCACATGGAAAGGC-3’; and GAPDH forward primer 5’-
TCACTGGCATGGCCTTCC-3’ and GAPDH reverse primer 5’-
GGCGGCACGTCAGATCC-3’.  Standards for MCAT-1, Pit-2, and GAPDH were 
prepared from amplifications purified using an E.Z.N.A® Gel Extraction Kit (Omega Bio-
tek, Inc., Doraville, GA, USA) and serially diluted.  All real-time PCR reactions were 
performed by amplifying 1 µL of cDNA in a 30 µL total volume with SYBR® Green PCR 
Master Mix (Applied Biosystems, Inc., Foster City, CA, USA) in an ABI PRISMTM 7700 
Sequence Detector (2 min at 50ºC, 10 min at 95ºC, and then 40 cycles of 15 sec at 95°C 
and 1 min at 60°C) [27-32].  Detection limits for each gene were determined by no 
template control.  The relative standard curve method, as described in ABI User Bulletin 
#2 Rev B: ABI Prism 7700 Sequence Detection System [33], was used to quantify the 
level of mRNA expression of the viral receptors MCAT-1 and Pit-2, and the results were 
expressed as relative to the expression levels of endogenous GAPDH, the reference 
gene.  Quantification of mRNA gene expression of MCAT-1 and Pit-2 viral receptors was 
conducted for each cell type at three different passages in triplicate for each passage.  
Results represent the average expression over the three separate passages.  
Quantification of mRNA gene expression of pluripotency markers Oct-4 and Nanog was 
based on the comparative CT method for each sample, as described in ABI User Bulletin 
#2 Rev B: ABI Prism 7700 Sequence Detection System [33], and expressed as relative 
expression normalized to the GAPDH endogenous reference gene and depicted as an 
 69
n-fold difference relative to the nonexposed.  Results represent the average expression 
over three separate exposure experiments.   
MTT assay for cell number.  To determine the effect of polymer exposure on 
growth rate, D3 and R1 mES and NIH 3T3 cells were plated in gelatin-coated 96-well 
tissue culture plates at 10,000 and 5,000 cells per well, respectively.  After two days of 
exposure at 37ºC to varying concentrations of PB and CSC, the number of viable cells 
was determined by an MTT assay, as previously described.[34]  Values for each point 
are the averages of triplicate wells.  Results are representative of three independent 
experiments.   
Alkaline phosphatase activity assay.  To measure the level of alkaline 
phosphatase activity in cells that had been incubated with polymer complexes, D3 and 
R1 mES cells and NIH 3T3 were plated in gelatin-coated 96-well tissue culture plates at 
10,000 and 5,000 cells per well, respectively, incubated (2 d, 37°C) with varying doses of 
Polybrene and chondroitin sulfate C, washed with PBS (100 µL per well), lysed for 10 
min with 0.1% Triton-X (100 μL per well), and then the alkaline phosphatase (ALP) 
activity in the lysates was quantified using the Alkaline Phosphatase Yellow (pNPP) 
Liquid Substrate System [35].  Incubation with pNPP (37ºC for 3-4 min) led to the 
development of a visible yellow color, the optical density of which was measured with an 
absorbance plate reader (VERSAmax; Molecular Devices, Sunnyvale, CA, USA) at 405 
nm.  Values for each point are the averages of triplicate wells.  Results are 
representative of three independent experiments.   
Transduction with polymers.  To measure the effect of the polymers on the 
efficiency of retrovirus transduction, D3 and R1 mES and NIH 3T3 cells were plated at 
3.5 x 105 and 1.5 x 105 cells per well, respectively, in gelatinized 6-well tissue culture 
plates.  The next day, equal weight concentrations of 80 µg per mL of cationic polymer 
 70
Polybrene (PB) and anionic polymer chondroitin sulfate C (CSC) were added to 
ecotropic MSCV-eGFP retrovirus stocks (from combined harvests with titers of 2.7 x 105 
and 4.1 x 105) and mixed by vortexing.  Virus and polymers were incubated together for 
20 min, and then centrifuged for 10 min at 10,300 g at room temperature.  The visible 
virus-polymer pellets were resuspended in fresh complete ES medium to the desired 
virus concentration.  Cells were transduced with 1 mL of concentrated virus per well, and 
plates were centrifuged for 30 min at 1,100 g at room temperature.  The viral 
supernatants were removed 24 hours later and replaced with fresh medium.  Two days 
later the level of gene transfer was evaluated by fluorescence microscopy, flow 
cytometry, and real-time PCR. 
Fluorescence microscopy.  Three days after transduction, epifluorescent and 
phase contrast images (10X) of D3 and R1 mES and NIH 3T3 cells were taken with an 
inverted epifluorescence microscope (IX-50; Olympus America, Inc., Melville, NY, USA).  
Images represent three independent experiments. 
Flow cytometry.  The percentage of eGFP+ cells and the mean fluorescence 
intensity of eGFP transgene expression in transduced D3 and R1 mES and NIH 3T3 
cells was determined 3 days post transduction via flow cytometry using a BD LSR 
analyzer (BD Biosciences, San Jose, CA, USA).  Nontransduced control and MSCV-
eGFP-transduced D3 and R1 mES and NIH 3T3 cells were trypsinized, pelleted, 
washed, and resuspended in 1X PBS plus 10% FBS to achieve a single-cell suspension.  
Ten thousand events were collected per sample.  Nontransduced cells served as 
negative controls and were used to monitor autofluorescence and set fluorescence 
thresholds.  Viable cells were gated using forward and side scatter properties. The mean 
fluorescence intensity of eGFP was determined by gating the eGFP+ cells in each 
sample.  Results are representative of two independent experiments.   
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Determination of relative transgene copy number by real-time PCR.  To 
determine the number of integrated eGFP transgenes per cell, the genomic DNA of 
transduced D3 and R1 mES and NIH 3T3 cells was extracted 3 days post transduction 
using the DNeasy® Tissue Kit (Qiagen Inc., Valencia, CA, USA), with RNase (Qiagen 
Inc., Valencia, CA, USA) treatment of DNA performed prior to lysis.  The sequences of 
the primers (Integrated DNA Technologies, Inc., Coralville, IA, USA) used to amplify the 
DNA were as follows:  eGFP forward primer 5’-AGCAAAGACCCCAACGAGAA-3’ and 
eGFP reverse primer 5’-GGCGGCGGTCACGAA-3’;  genomic GAPDH forward primer 
5’-CTCTGGCTCAGAGGGTTTGG-3’ and genomic GAPDH reverse primer 5’-
ACAGAAACCAGTGGGCTTTGA-3’.  Standards for genomic GAPDH and eGFP 
transgene were prepared from serially diluted amplicons purified using an E.Z.N.A® Gel 
Extraction Kit (Omega Bio-tek, Inc., Doraville, GA, USA).  All real-time PCR reactions 
were performed by loading 150 ng of DNA per tube in a 30 µL total volume with SYBR® 
Green Master Mix (Applied Biosystems, Inc., Foster City, CA, USA) in an ABI PRISM™ 
7700 Sequence Detector (2 min at 50ºC, 10 min at 95ºC, and then 40 cycles of 15 sec at 
95°C and 1 min at 60°C).  No template control reactions were used to determine the 
detection limits for each gene.  Quantification of the relative number of integrated 
transgenes was based on the relative standard curve method and expressed as the 
relative eGFP copy number normalized to the GAPDH endogenous reference gene with 
relative copy number in nontransduced control subtracted as background [33, 36].  
Values for each point are the averages of triplicate PCR tubes.  Results are 
representative of three independent experiments.   
Data analysis.  Data for all studies are representative of three independent 
experiments.  Data are summarized as the mean ± the standard deviation for at least 
triplicate samples.  Statistical analysis was performed with MINITAB® Release 12.23 
software (Minitab, Inc., State College, PA, USA) using a one-way analysis of variance 
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(ANOVA) for repeated measurements of the same variable.  The Tukey multiple 
comparison test was used to conduct pair wise comparisons between means. 
Differences at p < 0.05 were considered statistically significant.   
 
3.3 Results 
Technologies are needed to efficiently genetically modify embryonic stem cells. 
Recombinant retroviruses are one of the most promising gene transfer technologies 
currently available, yet they have proven relatively ineffective for genetically modifying 
ES cells.  One key reason is that expression of integrated retrovirus transgenes is often 
variegated or completely silenced.  As a result, most research efforts have focused on 
understanding and overcoming the mechanisms that ES cells use to shutdown retrovirus 
gene expression.  We wondered if retroviruses were also limited in their ability to 
transduce ES cells.   
We first asked which of four commonly used retrovirus pseudotypes - 
amphotropic, ecotropic, 10A1 or vesicular stomatitis virus G (VSV-G) - most efficiently 
transduce ES cells.  To answer this question, we generated the four types of murine 
leukemia retrovirus (MLV) stocks by transfecting GP2-293 packaging cells with the 
appropriate envelope protein expression vector and a murine stem cell retrovirus 
(MSCV) vector that encoded eGFP (Figure 3.1), and then measured their titers on D3 
and R1 murine embryonic stem cells (mES), and on murine NIH 3T3 fibroblasts as a 
positive control.  We found that both D3 and R1 mES cells were transduced most 
efficiently by ecotropic and VSV-G pseudotyped retroviruses, which had titers about two  
to four-fold higher than amphotropic and 10A1 pseudotyped viruses (Figure 3.2A).  We 
verified by an ELISA for the virus capsid protein (p30) that the number of particles in 
each virus stock was similar (Figure 3.2B), which eliminated the possibility that the 
differences in titer were simply due to differences in the number of particles applied to 
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the cells.  In all cases, virus titers were substantially lower (by 300 to 1000-fold) on ES 
cells than on NIH 3T3 cells (the titers of the amphotropic, ecotropic, 10A1, and VSV-G 
pseudotyped viruses on NIH 3T3 cells were 1.2 x 105 CFU/ml, 6.9 x 105 CFU/ml, 1.0 x 
105 CFU/ml, and 7.1 x 105 CFU/ml, respectively). 
To determine if mES cells express fewer amphotropic receptors (Pit-2; inorganic 
phosphate transporter 2) or ecotropic receptors (MCAT-1; mouse cationic amino acid 
transporter 1) than NIH 3T3 cells, we used real-time PCR to quantify the relative number 
of Pit-2 and MCAT-1 mRNA transcripts in D3, R1, and NIH 3T3 cells.  We found no 
statistically significant (p<0.05) differences in the expression of MCAT-1 and Pit-2 in the 










Figure 3.1.  Schematic diagram of the bicistronic MSCV-eGFP retroviral vector 
containing the MSCV long terminal repeat (LTR) promoter followed by a packaging 
sequence (Ψ+) , a multiple cloning site (MCS), the enhanced green fluorescent protein 















































































































Figure 3.2.  Retroviruses, when used to transduce D3 and R1 murine embryonic stem 
cells (mES), have significantly higher titers when they are pseudotyped with ecotropic or 
VSV-G envelope proteins than when they are pseudotyped with amphotropic or 10A1 
envelope proteins.  (A)  D3 (black bars) and R1 (white bars) cells, plated (350,000 
cells/dish) the previous day in gelatinized 35mm gridded dishes, were transduced with 
stocks of amphotropic (Ampho), ecotropic (Eco), 10A1, or VSV-G pseudotyped 
retroviruses that had been serially diluted in fresh medium and brought to 8 μg/mL 
Polybrene (PB).  Three days later, the number of clusters of transduced cells (eGFP+) 
was counted by epifluorescence microscopy and multiplied by the dilution factor to 
determine the virus titer.  Statistically significant differences (p<0.05) from the titers of 
both amphotropic and 10A1-pseudotyped viruses are denoted by an asterisk (*).  
Ecotropic and VSV-G titers were not significantly different statistically from one another. 
(B) The number of virus particles in each stock was quantified by an ELISA for the viral 

















































Figure 3.3.  D3, R1, and NIH 3T3 cells express similar levels of mRNA for the ecotropic 
(MCAT-1) and amphotropic (Pit-2) retrovirus receptors.  Total RNA was extracted from 
lysates of D3 (black bars), R1 (white bars), and NIH 3T3 (cross hatch) cells, reverse 
transcribed using oligo dT primers, and real-time PCR used to quantify the relative 
amount of cDNA normalized to GAPDH.  Each bar represents the mean ± standard 
deviation of three experiments with three replicates.  No statistically significant (p<0.05) 








These results indicate that retrovirus transduction of mES cells is not limited by 
the number of receptors they express, and suggest that increasing receptor expression 
is not likely to be an effective strategy for improving ES cell transduction.  We have 
previously found in other cell types (e.g., NIH 3T3 and HeLa cells) that retrovirus 
transduction is limited, in part, by the slow rate that retroviruses are delivered to the 
surfaces of the cells [37-39].  The rate that retroviruses reach the cells, and the 
efficiency of transduction, can be significantly increased by forming retrovirus-polymer 
complexes, which due to their large size, sediment rapidly onto the cells and significantly 
increase the number of genes transferred [15-17].  Transduction can be further improved 
by increasing the concentration of virus, which is accomplished by pelleting the virus-
polymer complexes and resuspending them in a smaller volume of cell culture medium.    
Based on these previous successes, we decided to determine if we could 
improve retrovirus transduction of mES cells by using retrovirus-polymer complexation to 
increase the number and rate that the viruses were delivered to the cells.  Given the 
sensitivity of mES cells to the conditions used to culture them, and the need to maintain 
their pluripotency, we first determined the doses of the polymers (Polybrene (PB) and 
chondroitin sulfate C (CSC)) that could be used without significantly reducing the viability 
or pluripotency of the cells.  To determine if PB and CSC were cytotoxic, we plated D3, 
R1, and NIH 3T3 cells in 96-well plates, exposed them to a range of equal weight 
concentrations of PB and CSC for two days, and then quantified the number of viable 
cells using the MTT assay (Figure 3.4A).  We found, that, in all cases, the number of 
viable cells present after two days of culture was significantly higher than the number of 
viable cells that were present immediately after they were plated, which indicates that 
the polymers were not cytotoxic, even at the highest doses tested.  Nevertheless, the 
growth rates of the cells did appear to decline with increasing doses of the polymers.  
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The number of viable cells was 40 percent lower in wells that contained 3200 μg/mL of 
each polymer than in wells that did not contain any polymer (Figure 3.4A). 
Next we tested if the polymers affected the pluripotency of the mES cells.  We 
plated D3, R1, and NIH 3T3 cells in 96-well and 6-well plates, incubated them for 2 days 
with a range of equal weight concentrations of PB and CSC, and then measured the 
amount of alkaline phosphatase (ALP) activity present in extracts of the cells (Figure 
3.4B, 96-well plates).  Interestingly, ALP activity was slightly higher (p<0.05) in cells that 
had been incubated with intermediate doses (80 to 1600 μg/mL) of the polymers than in 
cells that were incubated with 0 or 3200 μg/mL of each polymer (Figure 3.4B).  Cells that 
were incubated with the highest dose of polymers tested (3200 μg/mL) exhibited about 
the same amount of ALP activity as the cells that were not incubated with the polymers.  
As expected, ALP activity was much lower in NIH 3T3 cells than in mES cells.  To more 
fully assess the effect of the polymer complexes on their pluripotency, we incubated 
mES cells with a range of concentrations of the polymer complexes for two days, and 
then used real-time PCR to quantify the level of mRNA within the cells of the 
pluripotency markers Oct-4 and Nanog.  We found that Oct-4 expression did not change, 
regardless of how much polymer was added to the cells (Figure 3.4C).  Interestingly, 
Nanog expression increased (p<0.05) by as much as 4.5-fold in mES cells that were 
exposed to the polymers as compared to non-exposed control cells (Figure 3.4D). Taken 
together, these data suggest that the polymers do not adversely affect the pluripotency 
of mES cells.   
From these data, we concluded that virus-polymer complexes (which are formed 
using 80 μg/mL each of PB and CSC) could be concentrated up to 40-fold (for a final 
polymer concentration of 3200 μg/mL each) and used to transduce mES cells without 
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Figure 3.4.  High doses of Polybrene (PB) and chondroitin sulfate C (CSC) reduces the 
growth rate, but not the pluripotency, of D3 and R1 mESC.  D3 and R1 mES cells were 
plated (10,000 and 5,000 cells/well, respectively) in gelatinized 96-well tissue culture 
plates.  The next day, the number of D3 (▪▪▪▪), R1 (– —— ), and NIH 3T3 (– – ) cells was 
determined using the MTT assay, after which the cells were cultured with a range of 
equal weight concentrations of CSC and PB.  Two days later, the (A) number and (B) 
pluripotency of D3 (●), R1 (○), and NIH 3T3 (▲) cells was determined using the MTT 
and alkaline phosphatase (ALP) assays, respectively.  Each point represents the mean ± 
standard deviation of triplicate wells.  For both D3 and R1 mES cells, ALP activity in cells 
exposed to 80, 400, 800, and 1600 µg/ml of polymers was significantly different (p<0.05) 
from cells cultured without the polymers (i.e., 0 µg/ml).  Oct-4 (C) and Nanog (D) mRNA 
expression levels were also quantified.  D3 and R1 mES cells were plated (350,000 
cells/well) in gelatinized 6-well tissue culture plates, and then cultured the next day with 
a range of equal weight concentrations of CSC and PB.  Two days later, total RNA was 
extracted from lysates of D3 (black bars) and R1 (white bars) cells and reverse 
transcribed using oligo dT primers, and the relative amount of cDNA was quantified by 
real-time PCR and is reported as n-fold differences relative to cells that were cultured 
without the polymers (i.e., 0 µg/mL).  Each bar represents the mean ± standard deviation 
of three independent experiments.  Statistically significant (p<0.05) differences from cells 
that were not cultured with polymers are denoted with an asterisk (*).   
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ecotropic MSCV-eGFP retroviruses with 80 μg/mL each of PB and CSC at 37°C for 20 
minutes to form virus-polymer complexes, pelleted the complexes and resuspended 
them in a range of reduced volumes of fresh ES complete medium, and then used them 
to transduce D3, R1, and NIH 3T3 cells.  The cells were cultured in gelatin coated dishes 
in the presence of leukemia inhibitory factor (LIF) to maintain the embryonic stem cells in 
an undifferentiated state.  Three days later we visualized the cells by epifluorescence 
microscopy (Figure 3.5) and used flow cytometry to quantify the mean fluorescent 
intensity of the transduced cells (Figure 3.6) as a function of virus concentration.   
We found that for all the cell types tested, the number of eGFP+ cells increased 
with increasing concentrations of virus (Figure 3.5).  In D3 and R1 mES cells, however, 
eGFP expression in individual cells (i.e., their mean fluorescence intensity) remained 
consistently low and did not change when the concentration of virus was increased 
(Figure 3.6).  In contrast, both the number of transduced NIH 3T3 cells, (Figure 3.5) and 
the intensity of fluorescence within individual NIH 3T3 cells (Figure 3.6) increased with 
increasing doses of virus, although the amount of eGFP expressed per cell appeared to 
reach a maximum at the highest doses of virus tested.   For all concentrations of virus 
used, however, the mean fluorescence intensity of eGFP in NIH 3T3 was significantly 
higher (p<0.05) than in D3 and R1 mES cells.  
Given their low levels of eGFP expression, we wondered if mES cells contained 
fewer integrated transgenes than the NIH 3T3 cells.  To determine if this was the case, 
we transduced D3, R1, and NIH 3T3 cells with virus-polymer complexes that had been 
concentrated up to 40-fold, and then three days later used real-time PCR to quantify the 
number of integrated eGFP transgenes.  We found that the number of integrated eGFP 
transgenes in all the cell types increased as the dose of virus used to transduce them 
increased (Figure 3.7).  Interestingly, at all doses of virus tested, we found that mES 











Figure 3.5.  The number of transduced cells increases when ecotropic retrovirus is 
concentrated by complexation with Polybrene and chondroitin sulfate C.  Retrovirus-
polymer complexes were formed, pelleted, resuspended in fresh ES cell culture medium 
to their original volume (1X), or to one-fifth (5X) or to one-fortieth (40X) their original 
volume, added to gelatinized 6-well tissue culture plates that had been seeded the 
previous day with mES (D1 and R3; 350,000 per well) or NIH 3T3 (150,000 per well) 
cells, centrifuged (1,100 g, 30 min, 25°C), and then cultured at 37°C in a humidified 
tissue culture incubator.  Three days later the cells were visualized by phase contrast 














































































Figure 3.6.  Delivery of ecotropic virus, concentrated up to 40-fold by complexation with 
PB and CSC, increases transgene expression in NIH 3T3 cells, but not in D3 or R1 mES 
cells.  Retrovirus-polymer complexes were formed, pelleted, resuspended in fresh ES 
cell culture medium to their original volume (1X), or to one-fifth (5X), one-tenth (10X), 
one-twentieth (20X) or one-fortieth (40X) their original volume, added to gelatinized 6-
well tissue culture plates that had been seeded the previous day with mES (D3 and R1; 
350,000 per well) or NIH 3T3 (150,000 per well) cells, centrifuged (1,100 g, 30 min, 
25°C), and then cultured at 37°C in a humidified tissue culture incubator.  Three days 
later flow cytometry was used to quantify the mean fluorescence intensity of the 
transduced D3 (●) and R1 (○) mES cells and NIH3T3 cells (▲).  For all concentrations of 
virus used, the mean fluorescence intensity of eGFP in NIH 3T3 was significantly higher 
(p<0.05) than in D3 and R1 mES cells and denoted with an asterisk (*).  Each point 

















































































Figure 3.7.  Ecotropic retrovirus transfers fewer genes to mES cells than to NIH 3T3 
cells.  Retrovirus-polymer complexes were formed, pelleted, resuspended in fresh ES 
cell culture medium to their original volume, or to one-fifth (5X), one-tenth (10X), one-
twentieth (20X), or one-fortieth (40X) their original volume, added to gelatinized 6-well 
tissue culture plates that had been seeded the previous day with mES (D3 and R1; 
350,000 per well) or NIH 3T3 (150,000 per well) cells, centrifuged (1,100 g, 30 min, 
25°C), and then cultured at 37°C in a humidified tissue culture incubator.  Three days 
later the chromosomal DNA of D3 (●), R1 (○), and NIH 3T3 cells (▲) was isolated, and 
real-time PCR was used to quantify the number of integrated eGFP transgenes relative 
to the number of endogenous GAPDH genes.  Each point represents the mean ± 




3.4 Discussion  
 Embryonic stem (ES) cells are difficult to genetically modify with recombinant 
retroviruses, largely because they employ multiple mechanisms to silence retrovirus 
gene expression [40].  As a result, most strategies to improve retrovirus transduction of 
ES cells have focused on developing retroviral vectors that are resistant to silencing [14].  
As a potential complimentary strategy, we decided to determine to what extent retrovirus 
gene expression could be improved in ES cells by increasing the number of genes 
transferred.  To test this strategy, we formed ecotropic retrovirus – polymer complexes, 
concentrated them up to 40-fold, and then used them to transduce D3 and R1 murine 
ES cells, and NIH 3T3 murine fibroblasts as a control.  Gene transfer was highest when 
the most concentrated virus-polymer complexes were used, with increases in the 
number of integrated transgenes as high as 150-fold in D3 cells, 50-fold in R1 cells, and 
120-fold in NIH 3T3 murine fibroblasts.  Despite these large increases in gene transfer, 
gene expression increased only in NIH 3T3 murine fibroblasts.  Gene expression in D3 
and R1 cells remained low and virtually constant.  Interestingly, even though an 
equivalent amount of retrovirus was delivered to each cell type, up to ten-fold fewer 
transgenes integrated into D3 and R1 cells than in NIH 3T3 fibroblasts.  These results 
indicate that retrovirus gene expression in ES cells cannot be substantially increased by 
simply increasing the number of genes transferred. 
The observation that D3 and R1 cells integrated fewer transgenes than NIH 3T3 
cells suggests that ES cells are more restrictive than other cell types to steps in the 
retrovirus lifecycle that lead to integration of the retrovirus genome.  It is interesting to 
consider which step of transduction is restricted in ES cells.  Previous work has shown 
that the number of retrovirus genes transferred to cells is proportional to 1) the number 
of active viruses delivered to the cells, and 2) the overall efficiency with which post-
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delivery steps of transduction are completed [37].  Mathematically, this relationship can 
be expressed as follows: 
ηAG =  
where  is the number of genes integrated per cell,  is the number of active viruses 
delivered per cell, and 
G A
η  is the fraction of active viruses that successfully complete post-
binding steps of transduction.  Andreadis et al showed that the number of active viruses 
delivered per cell ( ) can be estimated from the following relationship: A
lDCaA voc4=  
where  is the average radius of the target cells,  is the diffusion coefficient of the 
virus,  is the initial concentration of active retrovirus at the start of the infection, and l  
 an integrated function of time, the diffusion coefficient, the half-life of the virus, and the 
radius of the target cells [37, 41].  Based on this relationship, we conclude that the 
differences we observed in gene transfer to ES and NIH 3T3 cells were most likely not 
due to differences in the amount of virus delivered to the cells.  This is because each cell 
type was incubated with exactly the same formulation of virus, which rules out the 
possibility that the cells were exposed to different concentrations of virus, or to viruses 
with different half-lives or diffusion coefficients.  Also, the radii of ES (4-7 µM) and NIH 
3T3 (7 µM) cells are similar, and could account for at most a 1.75-fold difference in the 
number of active viruses delivered per cell [37, 42].  Since ES cells are transduced up to 
10-fold less efficiently than NIH 3T3 cells, it is likely that ES cells significantly inhibit one 





We do not know which post-delivery step of transduction is inhibited.  One 
possibility is that ES cells express fewer retrovirus receptors than NIH 3T3 cells.  Our 
data suggests this is unlikely since we found that ES and NIH 3T3 cells express similar 
levels of mRNA for the ecotropic retrovirus receptor.  Nevertheless, we cannot exclude 
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the formal possibility that ES cells express fewer functional receptors on their surfaces 
than NIH 3T3 cells due to differences in the post-transcriptional regulation of the 
receptor.  Another possibility is that ES cells divide more slowly than NIH 3T3 cells, or 
that a smaller fraction of ES cells are in mitosis at any given time.  This would reduce the 
susceptibility of ES cells to transduction since retroviruses can only gain access to the 
nuclei of cells during mitosis, when their nuclear envelopes are disassembled [43, 44].  
Since retroviruses rapidly lose their activity within cells over time due to ‘intracellular 
decay’, the longer they are excluded from access to the nucleus, the less likely they will 
be able to successfully transduce a cell [45].  However, this is not likely to be the case in 
our experimental system since 1) both ES and NIH 3T3 cells rapidly divide (ES cells 
double every 12 to 17 hours [46-48] and NIH 3T3 cells double every 12 hours [37]), and 
2) similar percentages of ES (about 18%) and NIH 3T3 (21.5%) cells are in the G2/M 
phase of the cell cycle when they are rapidly dividing [42, 49].  Taken together, it seems 
likely that ES cells are more resistant to transduction than NIH 3T3 cells because they 
restrict one or more post-fusion steps of the retrovirus lifecycle, rather than because they 
bind fewer viruses, express fewer receptors, or divide more slowly than NIH 3T3 cells.  
Further experimentation is needed to identify the mechanisms by which ES cells restrict 
retrovirus infection. 
 Although it is of interest to understand and overcome the mechanisms by which 
ES cells restrict retrovirus integration, our results clearly show that the most significant 
obstacle that currently hampers the successful use of retroviruses with ES cells is the 
ability of ES cells to silence retrovirus transgene expression.  This conclusion is 
supported by our rather surprising finding that that even though the number of genes 
transferred to ES cells increased monotonically with an increase of up to 40-fold in virus 
concentration (which suggests that the ES cells did not become saturated with virus 
even at the highest doses tested), transgene expression remained virtually constant.  
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These findings suggest that the mechanisms by which ES cells silence transgene 
expression are not saturable and are not overcome by large increases in the number of 
integrated transgenes.  For these studies, we used MSCV-derived retrovirus vectors that 
have had their LTR regions modified to reduce their susceptibility to DNA methylation.  
But ES cells use multiple mechanisms to silence gene expression, each of which can act 
independently of one another, that include DNA methylation, histone deacetylation, and 
the binding of negative trans-acting factors [50] to regulatory and coding regions of the 
integrated transgenes [40, 51].  MSCV-derived retroviruses are resistant to DNA 
methylation, but they still retain a negative control region (NCR) and an enhancer direct 
repeat (DR) that are probably acted upon by ES cell encoded repressive transcription 
factors and trans-acting factors [11].  Retrovirus vectors are needed that are resistant to 
all the mechanisms used by ES cells to silence transgene expression. 
Interestingly, we noticed that ES cells, when exposed to increasing doses of 
retrovirus-polymer complexes, expressed higher levels of ALP activity and Nanog 
expression, both makers of ES cell pluripotency [52, 53].  In contrast, Oct-4 expression, 
another marker of ES cell pluripotency, did not change [54].  Although we can only 
speculate, it is possible that the virus-polymer complexes stimulate ES cells to 
upregulate expression of these pluripotency markers because they contain high levels of 
chondroitin sulfate glycosaminoglycans.  Several recent studies suggest that chondroitin 
sulfate proteoglycans and glycosaminoglycans play important roles in directing the fate 
of ES cells.  For example, Emami and Chaudhry found that chondroitin sulfate, when 
added to the gelatin used to culture murine ES cells in the absence of a feeder layer, 
increased ES cell self-renewal as evidenced by a 57% increase in the cell population 
and a 32% increase in the number of embryoid bodies they were able to form [55].   
Sirko et al found that chondroitin sulfate proteoglycans play an essential role in 
proliferation, self-renewal and cell fate of neural stem cells [56].  In our studies, ES cells 
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expressed higher levels of Nanog when they were incubated with virus-polymer 
complexes that contained chondroitin sulfate.  Nanog is a master regulator of self-
renewal and pluripotency in ES cells, and is rapidly downregulated when ES cells 
differentiate in vitro [57].  Interestingly, ES cells that overexpress Nanog maintain their 
pluripotency even in the absence of leukemia inhibitory factor (LIF), a growth factor that 
is normally required to prevent their differentiation [52, 53, 57].  These observations 
suggest that it may be possible to maintain ES cells in a pluripotent state while they are 
being genetically modified - without the need for LIF - by coupling gene transfer vectors 
to a carrier composed of chondroitin sulfate glycosaminoglycans or other compounds 
with similar properties. 
In summary, we have shown that retroviruses transfer significantly fewer genes 
to murine ES cells than to NIH 3T3 fibroblasts.  Future work should determine the 
specific mechanisms by which ES cells restrict retrovirus transduction.  Such work would 
improve our understanding of retrovirus-cell interactions, provide the basis for the design 
of more efficient retrovirus vectors, and may suggest novel strategies for inhibiting 
infectious diseases such as HIV-1. 
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QUANTITATIVE ANALYSIS OF RETROVIRAL AND LENTIVIRAL GENE TRANSFER  




4.1  Introduction  
Embryonic stem (ES) cells are a promising source of cells for cellular therapy 
because they are capable of differentiating into virtually any cell type in the body [1, 2].  
The genetic modification of ES cells further broadens their range of potential applications 
[3].  For example, genetic modification of ES cells can be used to study their 
development and differentiation, or to induce them to differentiate into a specific cell 
type, or to adopt a desired therapeutic phenotype [4, 5].  Genetic modification is also 
likely to prove useful for improving the efficacy and safety of ES cell transplantation.  
Genetic modification of ES cells could be used to reduce their immunogenicity, or to 
make them susceptible to a prodrug that could be administered to the patient should the 
transplanted cells form a tumor or teratoma [6, 7]. 
Recombinant retroviruses are an attractive tool for genetically modifying ES cells 
because they stably integrate their genetic material into the host cell genome, which 
makes long-term transgene expression possible, both in vitro and in vivo.  Unfortunately, 
it has proven difficult to successfully genetically modify ES cells with retroviruses, 
primarily because ES cells shutdown expression of the integrated transgenes [8].  The 
mechanisms by which ES cells silence gene expression include DNA methylation, 
histone deacetylation, and the binding of negative trans-acting factors to regulatory and 
coding regions of the integrated transgenes [8-10].  Silencing of retrovirus transgene 
expression can manifest itself shortly after transduction or after long-term culture or 
differentiation of modified ES cells.   
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Lentivirus vectors (derived from HIV) may not be as susceptible to silencing in 
ES cells as traditional retrovirus vectors (derived from the murine leukemia virus) [11].  
Pfeifer et al reported stable expression from lentivirus transgenes in proliferating murine 
ES cells [12].  Expression was maintained in the cells, even when they were cultured in 
vitro as embryoid bodies, or in vivo as teratomas.  Nevertheless, recent work suggests 
that lentiviruses are not entirely resistant to ES cell silencing mechanisms.  For example, 
Yao et al isolated ES cell clones, each of which contained a single copy of an integrated 
lentivirus transgene, and observed three distinct patterns of gene expression. One clone 
expressed the transgene, another exhibited variegated expression, and in a third 
expression was silenced.  Chromatin immunoprecipitation experiments suggested that 
expression in the silent clone was most likely shutdown by the same mechanisms used 
to shutdown retrovirus transgene expression [10].    
  Clearly, the silencing of integrated transgenes is a significant limitation of using 
retroviruses or lentiviruses to genetically modify ES cells.  Recently, we found that ES 
cells integrate fewer retrovirus transgenes than NIH 3T3 mouse fibroblasts, which 
suggests that inefficient transduction may be another limitation of using retroviruses to 
genetically modify ES cells [13].  Several cellular factors (e.g., Fv1, moesin, and 
TRIM5α) are known to impede or block one or more intracellular steps of retrovirus 
infection [14-19] in other cell types.  We do not know if these or other factors restrict 
transduction in ES cells.   
As a first step towards identifying the factors that impede transduction of ES 
cells, we examined the efficiency with which three key steps of transduction are 
completed in R1 murine ES cells and in NIH 3T3 murine fibroblasts, a cell type that is 
much more easily transduced.  Using recombinant murine leukemia virus (MLV)-derived 
retrovirus and HIV-1-derived lentivirus vectors, we quantitatively compared 1) the 
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amount of virus binding, 2) the number of integrated transgenes, and 3) the resulting 
level of gene expression.   
 
4.2  Materials and Methods 
Chemicals.  Gluteraldehyde, poly-L-lysine, 1,5-dimethyl-1,5-
diazaundecamethylene polymethobromide (Polybrene, PB), 1-(4,5-dimethylthiazol-2-yl)-
3,5-diphenylformazan (MTT), 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-Gal), 
IGEPAL CA-630, trypsin inhibitor (soybean), gelatin from bovine skin (Type B) and 
gelatin from porcine skin (Type A) were purchased from Sigma Chemical Co. (St. Louis, 
MO, USA).  Complete mini protease inhibitor cocktail tablets were purchased from 
Roche Diagnostics (Indianapolis, IN, USA).  Hydrogen peroxide 30%, bovine serum 
albumin fraction V (BSA), polyoxyethylene 20-sorbitan monolaurate (Tween 20), Triton-X 
and sodium dodecyl sulfate (SDS) were from Fisher Scientific (Pittsburg, PA, USA).  
Non-fat dry milk (blotting grade) was from Bio-Rad Laboratories (Hercules, CA, USA).  
Mouse anti-p30 antibody was purified from the supernatant of the CRL-1219 (ATCC, 
Rockville, MD, USA) hybridoma cell line, following standard procedures [20].  The goat 
polyclonal anti-p30 antibody (78S221) was from Quality Biotech (Camden, NJ, USA).  
The horseradish peroxidase conjugated rabbit anti-goat immunoglobulin G polyclonal 
antibody was from Zymed Laboratories (South San Francisco, CA).   
Plasmids.  The expression plasmid encoding the VSV-G (pMD.G) [21, 22] was 
from Scott Case.  The expression plasmid encoding the ecotropic (pFBMOSALF) 
envelope protein was from Stephen Russell [23].  The lacZ retroviral vector (pCMMP-
nlsLacZ) was from Michael Conte (Harvard Institute of Human Genetics).  The 
expression plasmid encoding the MLV RFP-Gag protein (pmRFP-N1) was purchased 
from Addgene (Addgene plasmid 1814; Cambridge, MA, USA) [24].  The lentiviral 
packaging construct (pCMV∆R8.91) was from Scott Case [21].  The lacZ lentiviral vector 
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(pTY-EFnlacZ) was purchased from NIH AIDS Research and Reference Reagent 
Program (Bethesda, MD, USA).  The expression plasmid encoding the GFP-Vpr protein 
(peGFPC3) was from Thomas Hope [25].   
Cell culture.  NIH 3T3 mouse fibroblasts were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM; Mediatech, Inc., Herndon, VA, USA) with 10% bovine calf 
serum (BCS; Hyclone Labs, Inc., Logan, UT, USA), and 100 U of penicillin and 100 µg of 
streptomycin (Hyclone Labs, Inc., Logan, UT, USA) per mL.  The packaging cell line 
GP2-293 was cultured on collagen-coated plates (BD Biosciences Discovery Labware, 
Bedford, MA, USA) in DMEM (Mediatech, Inc., Herndon, VA, USA) with 10% fetal bovine 
serum (FBS; Hyclone Labs, Inc., Logan, UT, USA) and 100 U of penicillin and 100 µg of 
streptomycin per mL.  The packaging cell line 293T was cultured in DMEM (Mediatech, 
Inc., Herndon, VA, USA) with 10% fetal bovine serum (FBS; Hyclone Labs, Inc., Logan, 
UT, USA) and 100 U of penicillin and 100 µg of streptomycin per mL.  Undifferentiated 
R1 murine embryonic stem (mES) cells, a kind gift from Todd McDevitt (Georgia Tech), 
were cultured on 0.1% porcine gelatin-coated tissue culture flasks and plated in ES 
Complete Medium (ES-DMEM; ATCC, Manassas, VA, USA) supplemented with 4mM L-
glutamine (Invitrogen Corp., Carlsbad, CA, USA), 150 M β-mercaptoethanol (Sigma 
Chemical Co., St. Louis, MO, USA), 10% heat-inactivated fetal bovine serum (ES Cell-
Qualified FBS; Invitrogen Corp., Carlsbad, CA, USA), 1% MEM non-essential amino 
acids (Invitrogen Corp., Carlsbad, CA, USA), 100 U of penicillin and 100 µg of 
streptomycin (Invitrogen Corp., Carlsbad, CA, USA) per mL, and 103 U of leukemia 
inhibitory factor (LIF; Chemicon International Inc., Ternecula, CA, USA) per mL.   
Production of recombinant retroviruses.  To generate stocks of RFP-lacZ 
retrovirus, GP2-293 cells, a HEK 293-based packaging cell line that stably expresses the 
retroviral gag and pol genes (Clontech Laboratories, Inc., Mountain View, CA, USA) [26], 
were plated in 0.01% poly-L-lysine-coated T175 flasks (12.5x106 cells) in DMEM that 
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contained heat inactivated FBS (10%) but no antibiotics.  The next day, Lipofectamine™ 
2000 (Invitrogen Corp., Carlsbad, CA, USA) was used according to the manufacturer’s 
recommendations to cotransfect the cells with 24 µg each of 3 plasmids:  the VSV-G 
envelope glycoprotein expression plasmid (pMD.G), the RFP-Gag protein expression 
plasmid (pmRFP-N1) and the retrovirus vector pCMMP-nlsLacZ.  Six hours after 
transfection, the medium was replaced with fresh 30 mL DMEM/FBS with antibiotics and 
again at 36 hours after transfection.  Virus-laden tissue culture medium was harvested 
every 12 hours at 48, 60, 72, and 84 hours post-transfection, filter-sterilized (0.45 µm), 
combined, aliquotted and then frozen (-80ºC) for later use.  Two separate rounds of 
RFP-lacZ retrovirus stock were generated.  To generate stocks of GFP-lacZ lentivirus, 
we followed the same procedure to cotransfect 293T cells, except with 18 µg each of 4 
plasmids:  the VSV-G envelope glycoprotein expression plasmid (pMD.G), the GFP-Vpr 
protein expression plasmid (peGFPC3), the lentivirus packaging construct pCMV∆R8.91 
and the lentivirus vector pTY-EFnlacZ.     
Measurement of lentivirus decay.  Frozen VSV-G and ecotropic lacZ lentivirus 
in culture medium was thawed and then incubated at 37ºC and 10% CO2.  Samples 
were taken approximately every 10 hrs and frozen at -80ºC.  At later times, the samples 
were thawed and used to transduce NIH 3T3 cells in the diluted titer assay.  Briefly, ten-
fold serial dilutions of the incubated virus were made in DMEM/BCS and PB (8 µg per 
mL).  A 1-mL amount per well was used to transduce NIH 3T3 cells that had been plated 
(7 x 104 per well) the previous day in 12-well plates.  The next day the viral supernatant 
was removed and the cells replenished with fresh medium.  Three days post 
transduction, the cells were fixed and stained for β-galactosidase activity with X-Gal.  
The number of colonies of lacZ+ NIH 3T3 cells (typically in clusters of 2, 4, 8, or 16 blue 
cells) was counted with the aid of a dissecting microscope.  At appropriate dilutions of 
virus, the clusters of blue cells were sufficiently spread over the well such that each 
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cluster arose from a single transduction event.  The number of clusters counted was 
multiplied by the dilution factor to determine CFU (i.e., the number of lacZ+ colony 
forming units) per mL. Values for each point are the averages of triplicate wells.  Results 
are representative of two independent experiments for each lacZ lentivirus pseudotype. 
The best-fit value for the virus decay rate (kd) was determined by using the method of 
least squares to fit experimental data for decay (Figure 1) to the following equation: 
dV
dt
k Vd= −                               [27] 
where  






1 2  
as previously described [28]. 
Diluted titer assay.  To determine virus titer, two-fold serial dilutions of VSV-G 
RFP-lacZ retrovirus and VSV-G GFP-lacZ lentivirus stocks were made in DMEM/BCS 
and Polybrene (8µg per mL).  Serially diluted virus (1 mL per well) was used to 
transduce NIH 3T3 cells that had been seeded at 2 x 104 cells per well in 6-well plates 
the previous day.  The viral supernatants were removed 5 hours later and replaced with 
fresh medium.  Three days post transduction, the cells were fixed and stained for β-
galactosidase activity with X-Gal [29].  The number of colonies of lacZ+ NIH 3T3 cells 
were counted with the aid of a dissecting microscope, and multiplied by the dilution 
factor to determine CFU (i.e., the number of lacZ+ colony forming units) per mL.  Titers 
for RFP-lacZ retrovirus stock #1, RFP-lacZ retrovirus stock #2 and GFP-lacZ lentivirus 
stock #1 were 4.57 ± 0.57 x 105 CFU/mL, 1.20 ± 0.61 x 105 CFU/mL, and 3.92 ± 1.04 x 
103 CFU/mL, respectively.  Results are the average of three independent experiments.   
Cell-associated virus assay.  Cell-associated and adsorbed VSV-G RFP-lacZ 
retrovirus and VSV-G GFP-lacZ lentivirus were analyzed by ELISA.  R1 mES cells and 
 101
NIH 3T3 cells were plated in gelatinized 6-well plates (3.5 x 105 and 1.0 x 105 per well, 
respectively).  The next day after plating, cells were transduced with 1 mL per well of 
either RFP-lacZ retrovirus or GFP-lacZ lentivirus and Polybrene (8 µg per mL) and LIF 
(103 U per mL), and plates were centrifuged for 30 min at 1,100 g at room temperature.  
Cells were incubated with virus for a range of times – immediately following 
centrifugation (0.5 hr), 1 hr, 2 hrs, and 7 hrs.  The virus supernatant was then collected, 
and the cells were washed once with PBS.  To remove loosely bound virus, cells were 
then treated with 1.25 mL non-enzymatic dissociation buffer (Sigma Chemical Co., St. 
Louis, MO, USA) for 10 min at room temperature.  Cells were collected from wells and 
centrifuged, and then the dissociation buffer supernatant was collected.  To determine 
levels of cell-associated virus (tightly-bound or absorbed virus), cell pellets were 
resuspended in 0.5 mL lysis buffer (1% Igepal, 150 mM NaCl and 50 mM Tris, pH 8) 
containing protease inhibitor (Complete Mini; Roche Diagnostics GmbH, Germany) and 
incubated on ice for 30 min, then centrifuged at 20,000 g for 10 min at 4°C to remove 
cellular debris.  The resulting supernatant was collected.  The virus supernatant, the 
dissociation buffer supernatant, and the cell lysate supernatant samples were stored at -
80°C for later analysis by ELISA.   
An enzyme-linked immunosorbent assay (ELISA) was used to determine the 
concentration of retrovirus p30 capsid protein or lentivirus p24 capsid protein in the 
supernatant samples collected above.  The p30 ELISA was conducted as described by 
Landázuri and Le Doux [30].  Values for replicate wells without virus were subtracted as 
background.  Values for each point are the average of triplicate wells.  Values for each 
point account for dilution factor and collection sample volume.  Results are 
representative of three independent experiments.   
For the p24 ELISA, an HIV-1 p24 Antigen ELISA kit (Zeptometrix Corp., Buffalo, 
NY, USA) was used according to manufacturer’s instructions.  The optical density of the 
 102
wells at 450 nm (OD450) was measured using an absorbance plate reader.  Values for 
replicate wells without virus were subtracted as background.  Optical density of the wells 
was converted to picograms of p24 using a standard curve. Values for each point 
account for dilution factor and collection sample volume.  Results are the average of 
three independent experiments done in duplicate.   
Confocal microscopy.  To quantify the number of virus particles associated with 
cells over time, R1 mES and NIH 3T3 cells were labeled for imaging by plating them on 
0.4% bovine gelatin-coated 12-well glass-bottom tissue culture plates (MatTek Corp., 
Ashland, MA, USA) at 350,000 and 70,000 cells per well, respectively.  Before plating, 
the glass-bottom plates were first treated with 1 mL per well of 1 N HCl for 15 min, rinsed 
three times with PBS, rinsed twice with distilled, deionized H2O and then coated with 
gelatin.  The next day after plating, cells were transduced with 1 mL per well of either 
RFP-lacZ retrovirus or GFP-lacZ lentivirus and Polybrene (8 µg per mL) and LIF (103 U 
per mL), and plates were centrifuged for 30 min at 1,100 g at room temperature.  
Transductions were stopped immediately following centrifugation, 1, 2, 7, and 14 hrs 
post transduction by placing the plates on ice.  After 30 min, the cells were incubated on 
ice with 1 mL per well of either ConcanavalinA488 (green) or ConcanavalinA594 (red) 
(diluted 1:750 in PBS) to stain the cell surface.  After 30 min, ConA was removed and 
cells were rinsed twice with PBS, then fixed with 4% paraformaldehyde (1 mL per well) 
for 10 min at room temperature.  The cells were washed twice with PBS, and then their 
nuclei were stained with DAPI (300nM in PBS) for 2 min at room temperature.  The cells 
were then washed twice with PBS.  All cells were visualized by confocal microscopy 
(Zeiss LSM 510, 40X oil objectives) and images were captured in z-series.  Three 
random z-series of cells were taken per well, and each time point was done in triplicate 
wells for each virus for each cell type.  3D projections were created for each z-series and 
ImageJ software analysis was used to count the number of cell-associated viruses for 
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two z-series per well and two wells per time point.  Results are the average of three 
independent experiments.   
Transduction assays.  To measure the level of lacZ expression per cell, R1 
mES and NIH 3T3 cells were plated in 0.1% porcine gelatin-coated, black/clear bottom 
96-well Costar® tissue culture treated assay plates (Fisher Scientific, Pittsburg, PA, 
USA) at 10,000 and 5,000 cells per well, respectively.  The next day, cells were 
transduced with 100 µL per well of either RFP-lacZ retrovirus or GFP-lacZ lentivirus 
mixed with 8 µg per mL of Polybrene and 103 U of LIF per mL, and plates were 
centrifuged for 30 min at 1,100 g at room temperature.  The viral supernatants were 
removed 24 hours later and replaced with fresh medium (200 µL per well).  Three days 
post transduction, the level of lacZ expression per cell was evaluated by alamarBlue® 
and FluoReporter® lacZ/Galactosidase Quantitation Kit assays (Invitrogen Corp., 
Carlsbad, CA, USA).  The day before conducting the assays, cells were replenished with 
100 µL per well of fresh medium. To determine the relative number of cells per well, 3 
hours prior to conducting the FluoReporter® assay, 25 µL per well of alamarBlue® 
reagent was added to the cells.  After three hours, absorbance values of the reduced 
alamarBlue® reagent (now red) due to cellular metabolic activity were read at 570 and 
600 nm using an absorbance plate reader (VERSAmax; Molecular Devices, Sunnyvale, 
CA, USA).  The percent reduction of alamarBlue® was then calculated according to 
manufacturer’s instructions.  Values for each point are the averages of triplicate wells.  
Results are representative of three independent experiments.   
Following the alamarBlue® assay, the levels of β-galactosidase activity per well 
were evaluated using the FluoReporter® assay.  The alamarBlue®-containing medium 
was removed and the cells washed once with 100 µL of PBS containing 1 mM MgCl2.  
After removal of the wash solution, 50 µL of lysis buffer (PBS with 1 mM MgCl2 and 0.5% 
IGEPAL) was added to each well, and the plate incubated at 37ºC.  After 30 min, 100 µL 
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of a 1.1 mM working solution of the 3-carboxy-umbelliferyl β-D-galactopyranoside (CUG) 
substrate reagent was added to each well, according to manufacturer’s instructions, and 
the plate incubated at room temperature up to 30 min.  The reactions were halted by 
addition of 50 µL per well of stop buffer (1 M Na2CO3).  The fluorescence of the solution 
in each well was measured using a fluorescent plate reader (Modulus™ Microplate 
Reader; Turner Biosystems, Sunnyvale, CA, USA).  Values for replicate wells without 
virus were subtracted as background.  To compare plates, a reference standard 
(provided by kit) was run on each plate.  Fluorescence values of the transduced samples 
were divided by the fluorescence of the reference standard on each individual plate.  A 
standard curve of serially diluted β-galactosidase was also used to determine the actual 
amount of β-galactosidase in each experimental well.  Values for each point are the 
averages of triplicate wells.  Results are representative of three independent 
experiments.    
Determination of relative transgene copy number by real-time PCR.  To 
determine the number of integrated nlacZ transgenes per cell, the genomic DNA of 
transduced R1 mES and NIH 3T3 cells was extracted 5 days post transduction using the 
DNeasy® Tissue Kit (Qiagen Inc., Valencia, CA, USA), with RNase (Qiagen Inc., 
Valencia, CA, USA) treatment of DNA performed prior to lysis.  The sequences of the 
primers (Integrated DNA Technologies, Inc., Coralville, IA, USA) used to amplify the 
DNA were as follows:  nLacZ forward primer 5’-TTCGCTACCTGGAGAGACGC -3’ and 
nLacZ reverse primer 5’-ATTTAGCGAAACCGCCAAGA-3’;  genomic GAPDH forward 
primer 5’-CTCTGGCTCAGAGGGTTTGG-3’ and genomic GAPDH reverse primer 5’-
ACAGAAACCAGTGGGCTTTGA-3’.  Standards for genomic GAPDH and nLacZ 
transgene were prepared from serially diluted amplicons purified using an E.Z.N.A® Gel 
Extraction Kit (Omega Bio-tek, Inc., Doraville, GA, USA).  All real-time PCR reactions 
were performed by loading 150 ng of DNA per tube in a 30 µL total volume with SYBR® 
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Green Master Mix (Applied Biosystems, Inc., Foster City, CA, USA) in a Bio-Rad iCycler 
(2 min at 50ºC, 10 min at 95ºC, and then 40 cycles of 15 sec at 95°C and 1 min at 
60°C).  No template control reactions were used to determine the detection limits for 
each gene.  Quantification of the relative number of integrated transgenes was based on 
the relative standard curve method and expressed as the relative nlacZ copy number 
normalized to the GAPDH endogenous reference gene with relative copy number in 
nontransduced control subtracted as background [31, 32].  Values for each point are the 
average of three independent transduction experiments done in triplicate.   
Data analysis.  Data are summarized as the mean ± the standard deviation for 
at least triplicate samples.  Statistical analysis was performed with MINITAB® Release 
12.23 software (Minitab, Inc., State College, PA, USA) using a one-way analysis of 
variance (ANOVA) for repeated measurements of the same variable.  The Tukey 
multiple comparison test was used to conduct pairwise comparisons between means. 
Differences at p < 0.05 were considered statistically significant.   
 
4.3  Results     
Previously we found that retroviruses integrate significantly fewer genes into the 
chromosomal DNA of murine embryonic stem (mES) cells than NIH 3T3 mouse 
fibroblasts.  We wanted to examine which steps in the transduction process were 
restricted in ES cell transduction.  To identify the key rate-limiting steps of transduction 
of ES cells, we quantitatively compared the levels of retrovirus and lentivirus binding, 
integration, and expression in R1 mES cells to those observed in cells that are easy to 
transduce: NIH 3T3 murine fibroblasts.   
To compare the efficiency of the initial binding steps of transduction in R1 mES 
and NIH 3T3 cells, we quantified the rate that fluorescently labeled retrovirus (RFP-lacZ) 
and lentivirus (GFP-lacZ) particles attach to and are adsorbed by R1 mES and NIH 3T3 
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cells.  We defined as "reversibly-bound” those viruses that were initially associated with 
the cells but came off when washed with an isotonic buffer.  We defined as "irreversibly-
bound” those viruses that remained associated with the cells even after these washes.  
R1 mES and NIH 3T3 cells were incubated with 1 mL per well of either RFP-lacZ 
retrovirus or GFP-lacZ lentivirus and 8 µg per mL PB, and immediately centrifuged for 30 
min at room temperature to deliver the viruses to the cells as a single cohort.  Cells were 
processed to quantify the levels of virus binding immediately following centrifugation, or 
1, 2, and 7 hours after the start of the incubation period.   
We wondered if differences in the rate that retroviruses and lentiviruses 
spontaneously lose their activity (i.e., decay) might differentially affect how many active 
viruses would ultimately end up bound to the cells in our virus binding assays.  We 
therefore estimated the fraction of viruses that lost their activity during the 30 minute 
virus binding step.  In a previous study, we showed that the half-life of retroviruses is 
about 7.5 hours at 37°C [30].  To determine if the half-life of lentiviruses were 
significantly different, we measured the half-life of lentiviruses at 37°C and found that 
ecotropic pseudotyped lentiviruses had a half-life of 17 ± 1.8 hours and VSV-G 
pseudotyped lentiviruses had a half-life of 19 ± 0.2 hours (Figure 4.1).  Based on these 
half-lives, we estimate that less than 2% of the lentiviruses and less than 5% of the 
retroviruses lose their activity during the virus binding step (which is mediated by 
centrifugation of the virus onto the cells for 30 minutes).  We concluded that the number 
of active viruses that bound to the cells was not significantly affected by differences in 














































































Figure 4.1.  The half-lives of ecotropic and VSV-G pseudotyped lentivirus are 
similar.  Stocks of lentivirus (lacZ) pseudotyped with either the ecotropic or VSV-G 
envelope protein were incubated at 37°C for a range of times up to 85 h.  Samples were 
taken at approximately every 10 h, frozen, later thawed and brought to 8 µg/mL PB, and 
then used to transduce NIH 3T3 cells.  Three days later, in the X-gal titer assay, the 
number of clusters of transduced cells were counted and multiplied by the dilution factor 
to determine the virus titer.  From the decay profiles, the half-life of ecotropic (A) and 
VSV-G (B) lacZ lentivirus was determined.  Each point shows the mean ± standard 
deviation of three replicates.   
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Following incubation of the viruses with the cells, the virus supernatant was 
collected and the cells treated with non-enzymatic dissociation buffer to remove 
reversibly-bound virus particles.  Cells were collected from the wells and pelleted by 
centrifugation to separate them from the dissociation buffer.  To determine the amount of 
irreversibly-bound virus, the pelleted cells were resuspended in lysis buffer.  Next, the 
amount of lentivirus (p24) and retrovirus (p30) capsid proteins present in the virus 
supernatant, dissociation buffer supernatant, and cell lysates were quantified by ELISA.  
We found that similar numbers of retroviruses were delivered to both R1 mES and NIH 
3T3 cells (Figure 4.2).  At one hour post transduction, about 30% of the retrovirus 
particles in the virus stock were delivered to both R1 mES (Figure 4.2A) and NIH 3T3 
(Figure 4.2B) cells and easily removed as reversibly-bound virus.  However, we found 
that up to 4-fold less retrovirus was irreversibly-bound to R1 mES cells than to NIH 3T3 
cells (Figure 4.2C).  Similarly, at one hour post transduction, 30% or more of the 
lentivirus particles in the virus stock were delivered to R1 mES (Figure 4.3A) and NIH 
3T3 (Figure 4.3B) cells and easily removed as reversibly-bound virus, while about 3-fold 
fewer lentiviruses irreversibly-bound to R1 mES cells than to NIH 3T3 cells (Figure 
4.3C).  
As an independent, parallel measure of virus adsorption, we used confocal 
immunofluorescence microscopy and image analysis software to quantitatively compare 
the number of cell-associated RFP-lacZ retrovirus and GFP-lacZ lentivirus particles 
(either bound or internalized) (Figure 4.4 A and B).  R1 mES and NIH 3T3 cells, seeded 
previously in gelatin-coated glass-bottom plates, were transduced with 1 mL per well of 
either RFP-lacZ retrovirus or GFP-lacZ lentivirus and 8 µg per mL PB and immediately 
centrifuged for 30 min at room temperature to deliver the viruses to the cells as a single 
cohort.  Cells were processed to quantify the levels of virus binding immediately 
following centrifugation, or 1 or 2 hours after the start of the incubation period.  Similar to 
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the biochemical assays of virus binding, image analysis showed that about 4-fold fewer 
retroviruses and lentiviruses bound to R1 mES cells than to NIH 3T3 cells (Figure 4.4C 





















































Figure 4.2.  Fewer retroviruses bind to R1 mES cells than to NIH 3T3 cells as 
determined by virus capsid ELISA.    RFP-lacZ retrovirus stocks were brought to 8 
µg/mL PB and then added to R1 mES and NIH 3T3 cells seeded the previous day at 3.5 
and 1.0 x 105 cells per well, respectively, in gelatin-coated 6-well plates.  After addition of 
the retrovirus stocks to the cells, the tissue culture dishes were centrifuged (30 min, 
1100 g, room temperature) and incubated for a range of times (0.5, 1, 2, and 7 h) at 
37°C in a humidified tissue culture incubator.  At the various times, the retrovirus 
supernatant was collected from the wells.  Cells were washed once with PBS and 
dislodged from the tissue culture plates with non-enzymatic dissociation buffer.  Cell 
suspensions were then centrifuged and the dissociation buffer supernatant was removed 
and collected.  Cell pellets were resuspended in cell lysis buffer.  The retrovirus 
supernatant, dissociation buffer supernatant, and cell lysate samples were analyzed for 
retrovirus concentration by p30 ELISA.  Values for each point account for dilution factor 
and collection sample volume.  The relative retrovirus in the original virus stock added to 
wells (- - - -) and in the retrovirus supernatant (▲) and dissociation buffer supernatant 
(■) are shown for R1 mES cells (A).  The relative retrovirus in the original virus stock 
added to wells (- - - -) and in the retrovirus supernatant (∆) and dissociation buffer 
supernatant (□) are shown for NIH 3T3 cells (B).  To determine the relative amount of 
tightly-bound virus (C) in the cell lysates in R1 mES (●)and NIH 3T3  (○) cells at various 
times, p30 levels were normalized to the levels of p30 in the original virus stock added to 
wells and to the number of cells per well at the start of the transduction (relative 
retrovirus number per cell).  Each point shows the mean ± standard deviation of three 
















































































































































Figure 4.3.  Fewer lentiviruses bind to R1 mES cells than to NIH 3T3 cells as 
determined by virus capsid ELISA.    GFP-lacZ lentivirus stocks were brought to 8 
µg/mL PB and then added to R1 mES and NIH 3T3 cells seeded the previous day at 3.5 
and 1.0 x 105 cells per well, respectively, in gelatin-coated 6-well plates.  After addition of 
the lentivirus stocks to the cells, the tissue culture dishes were centrifuged (30 min, 1100 
g, room temperature) and incubated for a range of times (0.5, 1, and 2 h) at 37°C in a 
humidified tissue culture incubator.  At the various times, the lentivirus supernatant was 
collected from the wells.  Cells were washed once with PBS and dislodged from the 
tissue culture plates with non-enzymatic dissociation buffer.  Cell suspensions were then 
centrifuged and the dissociation buffer supernatant was removed and collected.  Cell 
pellets were resuspended in cell lysis buffer.  The lentivirus supernatant, dissociation 
buffer supernatant, and cell lysate samples were analyzed for lentivirus concentration by 
p24 ELISA.  Levels of p24 in the original virus stock added to wells (- - - -) and p24 
levels in the retrovirus supernatant (▲) and dissociation buffer supernatant (■) are 
shown for R1 mES cells (A).   Levels of p24 in the original virus stock added to wells (- - 
- -) and p24 levels in the retrovirus supernatant (∆) and dissociation buffer supernatant 
(□) are shown for NIH 3T3 cells (B).  To determine the relative amount of tightly-bound 
virus (C) in the cell lysates in R1 mES (●) and NIH 3T3 (○) cells at various times, p24 
levels were normalized to the number of cells per well at the start of the transduction 
(lentivirus number per cell).  Each point shows the mean ± standard deviation of three 





















































































































Figure 4.4.  Fewer retroviruses and lentiviruses bind to R1 mES than to NIH 3T3 
cells as determined by immunofluorescence microscopy.  RFP-lacZ retrovirus and 
GFP-lacZ lentivirus stocks were brought to 8 µg/mL PB and then added to R1 mES and 
NIH 3T3 cells seeded the previous day at 3.5 x 105 and 7.0 x 104 cells per well, 
respectively, in glass-bottom, gelatin-coated 12-well plates.  After addition of the 
retrovirus and lentivirus stocks to the cells, the glass-bottom tissue culture dishes were 
centrifuged (30 min, 1100 g, room temperature) and incubated at 37°C for a range of 
times (0.5, 1, and 2 h).  At the various times, cells were removed from 37°C and chilled 
on ice for 30 min to block endocytosis.  Concanavalin-stained cells were fixed and then 
stained with DAPI to visualize cell nuclei.  Cells transduced with RFP-lacZ retrovirus (A) 
and GFP-lacZ lentivirus (B) were visualized by confocal microscopy.  The extent to 
which the RFP-lacZ retrovirus and GFP-lacZ lentivirus were cell-associated (bound or 
internalized) with R1 mES (C) and NIH 3T3 (D) cells was quantified using image 
analysis software (ImageJ).  Each point shows the mean ± standard deviation of three 





































































































































To compare the efficiency with which post-binding steps of transduction were 
completed within R1 mES and NIH 3T3 cells, we quantified the number of retrovirus and 
lentivirus transgenes that successfully integrated into the chromosomal DNA of the cells.  
We transduced R1 mES and NIH 3T3 cells with RFP-lacZ retrovirus and GFP-lacZ 
lentivirus, and then five days later used real-time PCR to quantify the number of 
integrated lacZ transgenes as referenced to the number of endogenous GAPDH genes.  
We found that about ten-fold fewer lentivirus lacZ transgenes and about three-fold fewer 
retrovirus lacZ transgenes integrated into R1 mES cells than in NIH 3T3 cells (Table 
4.1).   
Next, we wanted to compare the extent to which retrovirus and lentivirus 
transgenes were expressed in mES cells versus in NIH 3T3 fibroblasts.  To measure the 
efficiency of transgene expression per cell, we plated R1 mES and NIH 3T3 cells in 96-
well plates, transduced them with RFP-lacZ retrovirus and GFP-lacZ lentivirus stocks in 
the presence of 8 µg/mL PB.  Three days later we quantified the levels of β-
galactosidase activity in extracts of the cells, and normalized these levels to the number 
of viable cells.  We found that lentivirus and retrovirus transgene expression levels were 
8 to 11-fold lower, respectively, in R1 mES cells than in NIH 3T3 cells (Table 4.1).   
Taking together our virus binding, integration and transgene expression data, we 
estimated the efficiency with which retroviruses and lentiviruses completed the major 
steps in the transduction process in R1 mES cells relative to NIH 3T3 cells (Table 4.2).  
The relative efficiency of virus binding, virus integration and transgene expression in R1 
mES cells, as compared to NIH 3T3 cells, was about 25%, 130%, and 27%, 










Table 4.1.  R1 mES cells integrate fewer viral transgenes and demonstrate lower transgene expression levels per cell 
than NIH 3T3 cells.
1400 ± 1602.0 ± 0.63NIH 3T3
4.2 ± 1.2 †0.17 ± 0.02 †R1
1.8 ± 0.22
0.78 ± 0.19 *




Cell Type Relative TransgeneExpression Per Cell bVirus
34.0 ± 0.53
GFP-lacZ Lentivirus
122 ± 14 *
RFP-lacZ Retrovirus
a RFP-lacZ retrovirus and GFP-lacZ lentivirus stocks were brought to 8 µg/mL PB and then added to R1 mES and 
NIH 3T3 cells seeded the previous day at 1.5 x 105 and 7.0 x 104 cells per well, respectively, in gelatin-coated 12-well 
plates.  After addition of the retrovirus and lentivirus stocks to the cells, the tissue culture dishes were centrifuged (30 
min, 1100 g, room temperature), and then cultured at 37°C in a humidified tissue culture incubator.  Five days later the 
chromosomal DNA of R1 mES cells and NIH 3T3 cells was isolated, and real-time PCR was used to quantify the 
number of integrated lacZ transgenes relative to the number of endogenous GAPDH genes.  Each point shows the 
mean ± standard deviation of three independent experiments.
b RFP-lacZ retrovirus and GFP-lacZ lentivirus stocks were brought to 8 µg/mL PB and then added to R1 mES and 
NIH 3T3 cells seeded the previous day at 10,000 and 5,000 cells per well, respectively, in gelatin-coated 96-well plates.  
After addition of the retrovirus and lentivirus stocks to the cells, the tissue culture dishes were centrifuged (30 min, 1100 
g, room temperature), and then cultured at 37°C in a humidified tissue culture incubator.  Three days later, the 
retrovirus and lentivirus transgene expression levels and the number of cells per well were quantified using the 
FluoReporter® lacZ/Galactosidase Quantitation Kit assay and the alamarBlue® assay.  Each value shows the mean ± 
standard deviation of three replicates.
* Statistically significant differences (P ≤ 0.05) from NIH 3T3 cells transduced with RFP-lacZ retrovirus.













Table 4.2. Fractional efficiencies with which retroviruses and lentiviruses complete major steps in the 




(based on ELISA) *
1.30.30GFP-lacZ lentivirus
0.271.3RFP-lacZ retrovirus
Virus Integration † TransgeneExpression Per Cell †Virus
* The efficiency of binding was defined as the ratio of the values for binding based on the ELISA assay in R1 
mES cells to the values for binding in NIH 3T3 cells.  
† The efficiencies of post binding steps were defined as the ratio of the values in R1 mES cells to values in NIH 


















Retroviruses are an excellent tool for genetically modifying cells, but their use for 
transducing embryonic stem (ES) cells has met with limited success due to low 
transgene expression levels.  Expression levels are low because ES cells employ 
several mechanisms to efficiently silence integrated retrovirus transgenes.  We 
wondered if other steps of retrovirus transduction, in addition to gene expression, were 
restricted in ES cells.  Using recombinant MLV-derived retrovirus and recombinant HIV-
1-derived lentivirus vectors, we compared three major steps in the transduction of R1 
mES and NIH 3T3 cells: 1) the number of active virus particles that adsorb to cells in a 
given time as quantified by ELISAs for virus capsid proteins and by confocal microscopy 
and image analysis of fluorescently labeled virus particles; 2) the number of integrated 
transgenes as quantified by real-time PCR; and 3) the corresponding level of gene 
expression as quantified by the level of enzyme activity in extracts of the transduced 
cells.  We found that 3 to 4-fold fewer retroviruses and lentiviruses bound to R1 mES 
cells than to NIH 3T3 cells.  Interestingly, retroviruses and lentiviruses differed in the 
efficiency with which they completed post-binding steps of transduction.  We detected 
three-fold fewer integrated retrovirus transgenes, and 11-fold lower expression levels, in 
R1 mES cells than in NIH 3T3 cells, and 10-fold fewer integrated lentivirus transgenes, 
and 8-fold lower expression levels, in R1 mES cells than in NIH 3T3 cells.  These results 
suggest that both retroviruses and lentiviruses bind less efficiently to mES cells than to 
NIH 3T3 cells.  In addition, retrovirus transduction appears to be limited by low levels of 
transgene expression, whereas lentivirus transduction appears to be limited by inefficient 
post-binding steps of transduction.   
Our observation that R1 mES cells bind 3 to 4-fold fewer viruses than NIH 3T3 
cells may be due in part to differences in the sizes of the cells.   NIH 3T3 cells have 
previously been reported to have an average radius of about 7 µM, whereas mES cells 
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appear to be slightly smaller on average, with radii ranging from 4 to 7 µM [33].  
Andreadis et al showed that the number of active viruses delivered per cell ( ) is a 
function of the average radius of the cells being transduced and can be estimated from 
the following relationship: 
A
lDCaA voc4=  
where  is the average radius of the target cells,  is the diffusion coefficient of the 
virus,  is the initial concentration of active retrovirus at the start of the infection, and l  
 an integrated function of time, the diffusion coefficient, the half-life of the virus, and the 
radius of the target cells [33, 34].  This relationship indicates that differences in cell size 
can account for about a 2-fold difference in the number of active viruses delivered per 
cell, which suggests that factors other than differences in cell size may reduce the 





Interestingly, our data suggests that retroviruses complete post-binding steps of 
transduction as efficiently in mES cells as in NIH 3T3 cells. This is because the extent to 
which retrovirus integration was reduced in mES cells (about 3-fold) was similar to the 
extent to which binding was reduced (about 4-fold), which suggests that once bound, a 
retrovirus has about the same probability of successfully integrating its genetic material 
in the chromosomal DNA of mES cells as it would if it were bound to an NIH 3T3 murine 
fibroblast.  In contrast, out data suggests that lentiviruses do not complete post-binding 
steps of transduction as efficiently in mES as in NIH 3T3 cells.  This is because 4-fold 
fewer lentiviruses bound to mES cells than to NIH 3T3 cells, but 10-fold fewer integrated 
transgenes were detected in mES cells than in NIH 3T3 cells.  This suggests that a 
lentivirus, once bound to an mES cell, is nearly 3-fold less likely to successfully integrate 
its genetic material into the chromosomal DNA than if it had bound to an NIH 3T3 cell.  It 
is interesting to consider why lentiviruses, when infecting mES cells, are less likely to 
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successfully complete the intracellular steps of transduction.  Several host cell factors 
have been identified in other cell types that interfere with intracellular steps of retrovirus 
or lentivirus transduction.  For example, TRIM5α binds to incoming viruses, disrupts their 
ability to uncoat and to undergo reverse transcription, and marks them for degradation 
[16].  Another factor, moesin, when overexpressed in host cells, downregulates the 
formation of stable microtubules which reduces the efficiency of reverse transcription 
and hinders the movement of the retrovirus pre-integration complexes through the cell 
[17].  It would be interesting to determine if these, or other currently unidentified mES 
cell factors, interfere with post-binding steps of lentivirus transduction, and if so, to 
examine the mechanism by which they do so.   
Finally, our data suggests that lentivirus transgenes may be expressed more 
efficiently in mES cells than retrovirus transgenes.  This is because the extent to which 
lentivirus transgene expression was reduced in mES cells (about 8-fold) was similar to 
the extent to which the number of integrated transgenes was reduced (about 10-fold), 
which suggests that once integrated, a lentivirus provirus has about the same probability 
of being expressed in mES cells as it does in NIH 3T3 fibroblasts.  In contrast, the extent 
to which retrovirus transgene expression was reduced in mES cells (nearly 12-fold) was 
more significant than the extent to which the number of integrated transgenes was 
reduced (less than 3-fold), which suggests that once integrated, a retrovirus provirus is 
at about 4-fold less likely to be expressed in mES cells than in an NIH 3T3 fibroblast. 
Taken together, our results suggest that different strategies should be employed 
to improve retrovirus and lentivirus transduction of mES cells.  Retrovirus transduction 
would benefit most from the development of vectors that are resistant to the 
mechanisms by which mES cells shutdown gene expression.  In contrast, lentivirus 
transduction would benefit most from the identification of the specific intracellular steps 
of transduction that are rate-limiting, an understanding of the mechanisms by which 
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these steps impede transduction, and the development of strategies to improve the 
efficiency with which these steps are completed. 
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DEPLETION OF HISTONE H1 IN MURINE EMBYRONIC STEM CELLS AND 
TREATMENT WITH CYCLOSPORIN A DURING TRANSDUCTION DOES NOT 





Before the full potential of embryonic stem (ES) cells in regenerative medicine 
can be realized, techniques to genetically modify them must be improved.  Retroviral 
gene transfer to ES cells is particularly susceptible to gene silencing of integrated 
transgenes.  One of the most commonly proposed mechanisms for silencing of retroviral 
vectors in stems cells is histone modification [1].  Silenced retroviral transgenes are 
marked by a repressive histone code characterized by deacetylation of histones H3 and 
H4 and the recruitment of linker histone H1 [2, 3]. 
In particular, linker histone H1 plays a dynamic role in maintaining higher order 
chromatin structure, spacing nucleosomes on the chromatin fiber [4-6].  Linker histone 
H1 associates with the nucleosome at the DNA entry/exit points [4] and facilitates the 
folding of nucleosomes into compact structures [7-10].  H1 is thought to prevent 
unwinding of the DNA and directly results in condensed or “silent” chromatin, usually 
acting as a transcriptional repressor in gene expression regulation [11].  Previously, Yao 
et al found that silent retrovirus chromatin following infection was established with an 
8.4-fold hypoacetylation of histone H3 and 3.8-fold increase in linker histone H1 [1].   
We therefore hypothesized that reduction in expression of histone 1 may 
alleviate silencing of retrovirus transgenes.  To study the role of H1 in retroviral gene 
transfer, we transduced histone H1c, H1d, H1e triple null mouse embryonic stem cells 
with three different recombinant vectors – murine embryonic stem cell retrovirus 
(MSCV), and SIV and HIV-1 derived lentiviruses [12, 13].   
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5.2 Materials And Methods 
Chemicals.  Gluteraldehyde, 1,5-dimethyl-1,5-diazaundecamethylene 
polymethobromide (Polybrene, PB), and gelatin from porcine skin (Type A) were from 
Sigma Chemical Co. (St. Louis, MO, USA) 
Plasmids.  The expression plasmids encoding the were from Trent Spencer.  
The expression plasmid encoding the VSV-G (pMD.G) [14, 15] envelope protein was 
from Scott Case.  The murine stem cell virus retroviral vector (pMSCV-IRES-eGFP) was 
from Catherine Verfaillie [16, 17]. The lentiviral packaging construct (pCMV∆R8.91) was 
from Scott Case [14].  The lacZ lentiviral vector (pTY-EFeGFP) was purchased from NIH 
AIDS Research and Reference Reagent Program (Bethesda, MD, USA).  The SIV 
transfer vector (pCL20cSLFR), the SIV packaging construct (pCAG-SIVgprre), the SIV 
rev/tat plasmid (pCAG4-RTR-SIV), and a VSV-G envelope protein construct (pCAGGS-
VSVG) were all from Trent Spencer.   
Cell culture.  NIH 3T3 mouse fibroblasts, were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM; Mediatech, Inc., Herndon, VA, USA) with 10% bovine calf 
serum (BCS; Hyclone Labs, Inc., Logan, UT, USA), and 100 U of penicillin and 100 µg of 
streptomycin (Hyclone Labs, Inc., Logan, UT, USA) per mL.  The packaging cell line 
GP2-293 was cultured on collagen-coated plates (BD Biosciences Discovery Labware, 
Bedford, MA, USA) in DMEM (Mediatech, Inc., Herndon, VA, USA) with 10% fetal bovine 
serum (FBS; Hyclone Labs, Inc., Logan, UT, USA) and 100 U of penicillin and 100 µg of 
streptomycin per mL.  The packaging cell line 293T was cultured in DMEM (Mediatech, 
Inc., Herndon, VA, USA) with 10% fetal bovine serum (FBS; Hyclone Labs, Inc., Logan, 
UT, USA) and 100 U of penicillin and 100 µg of streptomycin per mL.  Undifferentiated 
D3 murine embryonic stem (mES) cells, obtained from ATCC, and undifferentiated F4 
(wild-type) and F6 (H1c/H1d/H1e null) mES cells, a kind gift from Yuhong Fan (Georgia 
Tech), were cultured on 0.1% porcine gelatin-coated tissue culture flasks and plated in 
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ES Complete Medium (ES-DMEM; ATCC, Manassas, VA, USA) supplemented with 
4mM L-glutamine (Invitrogen Corp., Carlsbad, CA, USA), 150 M β-mercaptoethanol 
(Sigma Chemical Co., St. Louis, MO, USA), 10% heat-inactivated fetal (ES Cell-
Qualified FBS; Invitrogen Corp., Carlsbad, CA, USA), 1% MEM non-essential amino 
acids (Invitrogen Corp., Carlsbad, CA, USA), 100 U of penicillin and 100 µg of 
streptomycin (Invitrogen Corp., Carlsbad, CA, USA) per mL, and 103 U of leukemia 
inhibitory factor (LIF; Chemicon International Inc., Ternecula, CA, USA) per mL.   
Production of recombinant retroviruses.  To generate stocks of MSCV-eGFP 
retrovirus, GP2-293 cells, a HEK 293-based packaging cell line that stably expresses the 
retroviral gag and pol genes (Clontech Laboratories, Inc., Mountain View, CA, USA) [18], 
were plated in 0.01% poly-L-lysine-coated T175 flasks (12.5x106 cells) in DMEM that 
contained heat inactivated FBS (10%) but no antibiotics.  The next day, Lipofectamine™ 
2000 (Invitrogen Corp., Carlsbad, CA, USA) was used according to the manufacturer’s 
recommendations to cotransfect the cells with 36 µg each of 2 plasmids:  the VSV-G 
envelope glycoprotein expression plasmid (pMD.G) and the retrovirus vector pMSCV-
IRES-eGFP.  Six hours after transfection, the medium was replaced with fresh 30 mL 
DMEM/FBS with antibiotics and again at 36 hours after transfection.  Virus-laden tissue 
culture medium was harvested every 12 hours at 48, 60, 72, and 84 hours post-
transfection, filter-sterilized (0.45 µm), combined, aliquotted and then frozen (-80ºC) for 
later use.  To generate stocks of HIV-1-eGFP lentivirus, we followed the same procedure 
to cotransfect 293T cells, except with 24 µg each of 3 plasmids:  the VSV-G envelope 
glycoprotein expression plasmid (pMD.G), the lentivirus packaging construct 
pCMV∆R8.91 and the lentivirus vector pTY-EFeGFP.  To generate stocks of SIV-eGFP 
lentivirus, we followed the same procedure to cotransfect 293T cells, except with 4 
plasmids: 30 µg of the SIV transfer vector (pCL20cSLFR), 18 µg of the SIV packaging 
 129
construct (pCAG-SIVgprre), 6 µg of the the SIV rev/tat plasmid (pCAG4-RTR-SIV), and 6 
µg of the VSV-G envelope glycoprotein expression plasmid (pCAGGS-VSVG). 
  Diluted titer assay.  To determine virus titer, ten-fold serial dilutions of 
MSCV-eGFP virus stock (from 48 hr harvests) were made in ES Complete Medium and 
Polybrene (8µg per mL).  Serially diluted virus (1 mL per dish) was used to transduce D3 
and R1 mES and NIH 3T3 cells that had been seeded at 3.5 x 105 and 1.5 x 105 cells 
per dish, respectively, in 35 mm gridded (2 mm) dishes (Nalge Nunc International, 
Rochester, NY, USA).  The viral supernatants were removed 24 hours later and replaced 
with fresh medium.  Three days post transduction, the number of clusters of eGFP+ 
mES and NIH 3T3 cells (typically in clusters of 2, 4, 8, or 16 green cells) were counted 
with the aid of an inverted epifluorescence microscope (IX-50; Olympus America, Inc., 
Melville, NY, USA), and multiplied by the dilution factor to determine the titer (i.e., the 
number of eGFP+ colony forming units (CFU) per mL).  Results are representative of 
three independent experiments. 
Transduction with viral vectors.  To evaluate gene transfer, D3, F4, and F6 
mES and NIH 3T3 cells were plated at 3.5 x 105 and 1.5 x 105 cells per well, 
respectively, in gelatinized 6-well tissue culture plates.  The next day, 8 µg per mL of 
cationic polymer Polybrene (PB) was added to VSV-G MSCV-eGFP, VSV-G SIV-eGFP, 
and VSV-G HIV-1-eGFP virus stocks and mixed by vortexing.  Cells were transduced 
with 1 mL of virus per well, and plates were centrifuged for 30 min at 1,100 g at room 
temperature.  The viral supernatants were removed 24 hours later and replaced with 
fresh medium.  Three days later the level of gene transfer was evaluated by 
fluorescence microscopy, flow cytometry, and real-time PCR. 
Fluorescence microscopy.  Three days after transduction, epifluorescent and 
phase contrast images (10X) of D3 mES cells were taken with an inverted 
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epifluorescence microscope (IX-50; Olympus America, Inc., Melville, NY, USA).  Images 
represent three independent experiments. 
Flow cytometry.  The percentage of eGFP+ cells in transduced D3 and R1 mES 
cells was determined 3 days post transduction via flow cytometry using a BD LSR 
analyzer (BD Biosciences, San Jose, CA, USA).  Nontransduced control and transduced 
cells were trypsinized, pelleted, washed, and resuspended in 1X PBS plus 10% FBS to 
achieve a single-cell suspension.  Thirty thousand events were collected per sample.  
Nontransduced cells served as negative controls and were used to monitor 
autofluorescence and set fluorescence thresholds.  Viable cells were gated using 
forward and side scatter properties.  Results are representative of three independent 
experiments.   
Determination of relative transgene copy number by real-time PCR.  To 
determine the number of integrated eGFP transgenes per cell, the genomic DNA of 
transduced D3 mES cells was extracted 5 days post transduction using the DNeasy® 
Tissue Kit (Qiagen Inc., Valencia, CA, USA), with RNase (Qiagen Inc., Valencia, CA, 
USA) treatment of DNA performed prior to lysis.  The sequences of the primers 
(Integrated DNA Technologies, Inc., Coralville, IA, USA) used to amplify the DNA were 
as follows:  eGFP forward primer 5’-AGCAAAGACCCCAACGAGAA-3’ and eGFP 
reverse primer 5’-GGCGGCGGTCACGAA-3’;  genomic GAPDH forward primer 5’-
CTCTGGCTCAGAGGGTTTGG-3’ and genomic GAPDH reverse primer 5’-
ACAGAAACCAGTGGGCTTTGA-3’.  Standards for genomic GAPDH and eGFP 
transgene were prepared from serially diluted amplicons purified using an E.Z.N.A® Gel 
Extraction Kit (Omega Bio-tek, Inc., Doraville, GA, USA).  All real-time PCR reactions 
were performed by loading 150 ng of DNA per tube in a 30 µL total volume with SYBR® 
Green Master Mix (Applied Biosystems, Inc., Foster City, CA, USA) in an ABI PRISM™ 
7700 Sequence Detector (2 min at 50ºC, 10 min at 95ºC, and then 40 cycles of 15 sec at 
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95°C and 1 min at 60°C).  No template control reactions were used to determine the 
detection limits for each gene.  Quantification of the relative number of integrated 
transgenes was based on the relative standard curve method and expressed as the 
relative eGFP copy number normalized to the GAPDH endogenous reference gene [19, 




Given the relative ineffectiveness of retroviral gene transfer to embryonic stem 
(ES) cells due to silencing, we wondered if silencing could be ameliorated in mES cells 
triple null for linker histone H1 and how retroviral gene transfer would then compare to 
two other commonly used lentiviral vectors.   
We first wanted to characterize our virus stocks by measuring their titer on 
murine NIH 3T3 fibroblasts.  We found that our MSCV-eGFP retrovirus stocks had the 
highest titer, about 4-fold higher than SIV-eGFP lentivirus and 100-fold higher than HIV-
eGFP lentivirus stocks (Table 5.1).   
We next evaluated how many transgenes our virus stocks delivered to 
undifferentiated ES cells.  We transduced D3 mES cells with our three different virus 
stocks with 8 µg/mL of Polybrene (PB) added and 5 days later used real-time PCR to 
quantify the number of eGFP transgenes.  We found that the relative number of genes 
transferred to D3 mES cells by each virus corresponded well with the titer found on NIH 
3T3 cells (Table 5.1). However, the intensity of fluorescence within individual cells 
(Figure 5.1) was not indicative of the number of transgenes integrated.  MSCV-eGFP 
retrovirus had the highest titer and delivered more transgenes to D3 mES cells.  
However, D3 mES cells transduced with MSCV-eGFP demonstrated a lower intensity of 
fluorescence in individual cells than D3 mES cells transduced with either HIV-1-eGFP 
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and SIV-eGFP lentiviruses, suggesting a degree of silencing of the integrated retroviral 










































a NIH 3T3 cells, plated (70,000 cells/well) the previous day in 12-well tissue culture 
plates, were transduced with stocks of VSV-G pseudotyped MSCV-eGFP retrovirus, 
SIV-eGFP lentivirus, or HIV-1-eGFP lentivirus that had been serially diluted in fresh 
medium and brought to 8 μg/mL Polybrene (PB).  Three days later, the number of 
clusters of transduced cells (eGFP+) was counted by epifluorescence microscopy and 
multiplied by the dilution factor to determine the virus titer.  Each value is the mean ± 
standard deviation of three replicates. 
b Virus stocks with 8 μg/mL Polybrene (PB) added were used to transduce gelatinized 6-
well tissue culture plates that had been seeded the previous day with D3 mES cells 
(350,000 per well) .  Cells were centrifuged (1,100 g, 30 min, 25°C), and then cultured at 
37°C in a humidified tissue culture incubator.  Five days later the chromosomal DNA of 
D3 (●), R1 (○), and NIH 3T3 cells (▲) was isolated, and real-time PCR was used to 
quantify the number of integrated eGFP transgenes relative to the number of 
endogenous GAPDH genes.  Each point represents the mean ± standard deviation of 





















Figure 5.1.  Transduction of D3 mES cells with SIV-eGFP lentivirus and HIV-1-eGFP 
lentivirus shows higher transgene expression per individual cell than with MSCV-eGFP 
retrovirus.  Retrovirus and lentivirus stocks, with 8 µg/mL PB added, were used to 
transduce D3 mES cells seeded the previous day (350,000 cells per well) in gelatinized 
6-well tissue culture plates.  Cells were centrifuged (1,100 g, 30 min, 25°C) and then 
cultured at 37°C in a humidified tissue culture incubator.  Three days later the cells were 















To determine the effects of H1 in viral gene transfer, we next transduced F6 mES 
cells null for three H1 genes – H1c, H1d,H1e – which have 50% of the normal level of 
H1, along with wild-type F4 mES cells of the same cell line.   Three days following 
transduction, we evaluated the number of eGFP+ cells by flow cytometry.  Interestingly, 
we found that triple null F6 mES cells did not improve viral gene transfer and had about 
a 2-fold reduction in the number of eGFP+ cells for all three viruses in comparison to 



























































Figure 5.2.  Triple null F6 mES cells have 2-fold fewer eGFP+ cells than wild-type F4 
mES cells when transduced with all three virus stocks.  Retrovirus and lentivirus stocks, 
with 8 µg/mL PB added, were used to transduce F4 (black bars) and F6 (white bars) 
mES cells seeded the previous day (350,000 cells per well) in gelatinized 6-well tissue 
culture plates.  Cells were centrifuged (1,100 g, 30 min, 25°C) and then cultured at 37°C 
in a humidified tissue culture incubator.  Three days later, the number of eGFP+ cells 
was determined by flow cytometry.  Values represent the mean ± standard deviation of 
triplicate measurements.  Statistically significant differences (P ≤ 0.05) from transduction 






Most strategies to reduce silencing of retroviral transgenes involve improving 
retroviral vector design.  In an alternative strategy, we decided to determine if gene 
transfer to murine embryonic stem (mES) cells could be improved by depletion of the 
linker histone H1, which has been implicated in retrovirus silencing.  We compared three 
different commonly used viral vectors – MSCV, SIV, and HIV-1 – in mES cells.  The 
number of virus integrated transgenes correlated well with titers for our three different 
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virus stocks.  We transduced triple null F6 mES cells and wild-type F4 mES cells with 
the three different viruses and found that transduced triple null F6 mES cells showed a 
2-fold reduction in the number of eGFP+ cells for all three viruses in comparison to F4 
wild-type mES cells.   
The observation that triple null F6 mES cells had about a 2-fold reduction in the 
number of eGFP+ cells following transduction with all three viruses in comparison to 
wild-type F4 mES cells may offer interesting implications for understanding virus 
integration patterns.  Retroviruses were originally thought to integrate randomly, but 
recent studies have challenged this notion.  Studies have now shown that murine 
leukemia virus (MLV)-derived retroviral vectors prefer to integrate at transcription start 
sites, and lentiviral vectors derived from simian immunodeficiency virus (SIV) and human 
immunodeficiency virus  type 1 (HIV-1) target integration within transcription units and 
gene-dense regions of the genome [21].  More specifically, Beard et al found that MLV-
derived and HIV-derived vectors integrated near genes involved in growth and survival 
[22].   
Fan et al, who derived the triple null mES cells, found that depletion of H1 in the 
triple null mES cells lead to highly specific changes in gene expression in comparison to 
wild-type mES cells.  Thirty-eight genes were upregulated and 10 genes were 
downregulated 2-fold or more (p ≤ 0.05) in triple null mES cells in comparison to wild-
type mES cells [13].  The genes that were downregulated include: IGF-II, insulin receptor 
substrate-2 (Irs2), H2B histone family member S (H2bfs), cytoplasmic beta-actin, zinc 
finger protein regulator of apoptosis and cell cycle arrest (Zac1), proliferin, neural 
precursor cell expressed developmentally downregulated Nedd9 (Nedd9), Vanin-1, BCL-
6, and desmocollin type 2 (DSC2) [13].  Several of these genes are involved in 
controlling cell growth and survival.  Taken together with the 2-fold reduction in the 
number of eGFP+ cells in triple null F6 mES cells that we observed, it is possible that 
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our viral vectors targeted these down-regulated genes for integration.  Viral vectors 
targeting these genes for integration may not have been effectively expressed, leading 
to a drop in the number of eGFP+ cells.    
If so, we have identified several candidate genes that are readily targeted by 
retroviral and lentiviral vectors for integration in undifferentiated mES cells.  Further work 
analyzing the genomic motifs or cellular proteins associated with these and similar 
genes is then warranted in order to design viral vectors capable of directed integration 
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6.1 Summary of results 
 
In Chapter 2 we constructed two MSCV-derived retroviral vectors encoding for 
proendocrine transcription factors Ngn3 and PDX-1.  We genetically modified mES cells 
with our Ngn3 retrovirus to ectopically express Ngn3, and we found its overexpression 
was followed by a 2-fold upregulation at 5 days post transduction of NeuroD1/Beta2, 
Pax4, Dll-1, and PDX-1, other important proendocrine transcription factors whose 
expression is regulated by or downstream of Ngn3.  These results suggest that 
pluripotent mES cells may be competent to respond to Ngn3 and support our hypothesis 
that ectopic expression of these factors can be used to induce mES cells to adopt an 
endocrine fate.  However, following long-term culture and embryoid body differentiation, 
expression of most proendocrine transcription factors decreased.  In addition, our 
retrovirus transduction methods were inefficient for gene transfer to mES cells, 
demonstrated by low transgene expression levels of both Ngn3 and the eGFP reporter 
gene in EFC1 mES cells in comparison to NIH 3T3 fibroblasts, an easy to transduce cell 
type.   
 In Chapter 3 we investigated whether delivering more transgenes would 
improve retroviral gene transfer to murine embryonic stem (mES) cells.  We formed 
polymer complexes with MSCV-derived ecotropic retroviruses, concentrated them up to 
40-fold, and transduced two different murine embryonic stem cell lines, and a mouse 
fibroblast cell line as a control.  The number of integrated transgenes increased more 
than 50-fold in the embryonic stem cell lines, yet, surprisingly, transgene expression did 
not increase.  Interestingly, the embryonic stem cells had significantly fewer integrated 
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transgenes than the mouse fibroblasts, even though transduction conditions were 
identical, which suggests that embryonic stem cells may restrict a post-binding step of 
retrovirus transduction.   
In Chapter 4 we investigated which steps of the virus lifecycle restrict efficient 
transduction of ES cells as compared to a cell type that is much more easily transduced 
(i.e., NIH 3T3 murine fibroblasts).  Using recombinant MMuLV-derived retrovirus and 
recombinant HIV-1-derived lentivirus, we compared three major steps in the transduction 
of R1 mES and NIH 3T3 cells: 1) the number of active virus particles that absorb to cells 
in a given absorption time using ELISA assays and confocal microscopy and image 
analysis; 2) the number of integrated transgenes using real-time PCR; and 3) the 
corresponding level of gene expression.  We found that retroviruses and lentiviruses 
similarly bind 3 or 4-fold less efficiently to R1 mES cells than to NIH 3T3 cells.  R1 mES 
cells integrated 3-fold fewer retrovirus transgenes than NIH 3T3 cells and showed 11-
fold lower retrovirus transgene expression levels.  In comparison, R1 mES cells 
integrated 10-fold fewer lentivirus transgenes than NIH 3T3 cells and showed 8-fold 
lower lentivirus transgene expression levels.  Although silencing remains the biggest 
obstacle to retroviral gene transfer, these results indicate virus binding and integration in 
the transduction process are also limiting in ES cells.   
In Chapter 5 we investigated whether depletion of histone 1 would alleviate 
silencing of retrovirus transgenes and improve gene transfer.  To study the role of H1 in 
retroviral gene transfer, we transduced histone H1c, H1d, H1e triple null mouse 
embryonic stem cells with three different recombinant vectors – murine embryonic stem 
cell retrovirus (MSCV), and SIV and HIV-1 derived lentiviruses.  We found that 
transduction of mES cells depleted of histone H1 did not improve viral gene transfer, and 
triple null mES cells had about a 2-fold reduction in the number of eGFP+ cells for all 
three viruses in comparison to wild-type mES cells.   
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6.2 Conclusions 
In conclusion, we determined: 
1. The number of integrated transgenes delivered to murine embryonic 
stem (mES) cells can be increased with virus concentration, but 
transgene expression does not increase; mES cells integrate fewer 
transgenes than easily transduced NIH 3T3 cells.  
2. Binding and integration of both retroviruses and lentiviruses is 
restricted in mES cells. 
3. Depletion on linker histone H1 in mES cells does not improve gene 
transfer. 
 
6.3 Future Considerations 
The following are suggestions for future research: 
1. Although we could increase the number of transgenes delivered to mES cells, 
expression of integrated transgenes remained low.  Future work should continue 
to focus on improving retroviral vector design to decrease retrovirus 
susceptibility to silencing.   
2. Complexation of virus with polymers proved an effective way to concentrate 
retrovirus and increase the number of transgenes delivered to mES cells.  
Complexation with polymers should also be applied to lentiviruses to study the 
relationship between virus dosage and transgene expression to standardize 
gene transfer protocols for ES cells using lentiviruses. 
3. We found that mES cells expressed similar levels of mRNA for the ecotropic and 
amphotropic retrovirus receptors as NIH 3T3 cells.  Future work should evaluate 
the number of functional receptors at the cell surface of mES cells and whether 
gene transfer can be improved by upregulating receptor expression.   
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4. We found that mES cells integrated 10-fold fewer lentiviral transgenes than NIH 
3T3 cells.  Future work should determine if host cell factors restricting the 
lentivirus life cycle are more highly expressed in undifferentiated ES cells.   
5. We found that gene transfer to ES cells was not improved through depletion of 
linker histone H1 in mES cells.  Further work should investigate the effects of 
alternative modifications to chromatin structure on gene transfer to develop more 














A.1  Confocal Microscopy Image Analysis to Determine Number of Cell-Associated 
Virus Particles 
 
In LSM Image Browser: 
 
1. Converst z-stack series of confocal microscopy images to 3-D projection to combine 
all image slices 
 
a. Open z-stack series taken using Zeiss LSM 510 confocal microscope 
 
b. Conduct Projection of image 
 
i. Use Projection button 
 
ii. Settings:   
 
1. Projection: set turning axis, number of projections, difference 
angle as desired 
 
2. Transparency: Maximum 
 
iii. Hit Apply 
 
c. Save new “Total Projection image” – these projection images are created to 
measure total virus particles in confocal microscopy z-stack series 
 
2. Create projection images of just cell regions 
 
a. Select cell regions on new “Projection image” – these projection images are 
created to measure only cell-associated virus particles in confocal microscopy 
z-stack series 
 
b. Use Overlay button 
 
i. In Overlay options use Closed Free Shape button to select cell regions 
with cell-associated virus particles (must used Closed region button, 
not Open region); typically 1-3 regions needed per cell  
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ii. Once regions selected, highlight regions, move highlighted boxes to 
make adjustments 
 
iii. Once all cell regions selected, make sure all regions are not 
highlighted 
 
c. Extract regions into new window 
 
i. Use Extract Regions button 
 
d. Save new “Cell Region Projection image” 
 






4. ImageJ can open projection images created in the LSM Image Browser 
 
5. Determine background levels for each color channel 
 
a. Use Control Projection images created above 
 
b. Image – Adjust – Brightness/Contrast 
 
6. Determine Number of Cell-Associated Virus Particles 
 
a. Open “Cell Region Projection image” created above in LSM Image Browser; 
make sure image separated into 3 color channel images 
 
b. Select appropriate color channel with just virus particles 
 
i. Red Channel: RFP-gag retrovirus 
 
ii. Green Channel GFP-vpr lentivirus 
 
c. Adjust Brightness/Contrast to eliminate background 
 
i. Hit “Yes” to Apply to all slices when prompted 
 
d. Make sure to return to first slice showing virus particles  
 
e. Run Count Virus Particles Macro (created by Jamie Chilton) 
 
i. Hit “Yes” to Apply to all slices when prompted 
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f. Organize/label data reports generated by Macro in Excel 
 
i. Reports record particle number, particle size, average particle size, 
total particle count 
 
g. Save new image of counted virus particles generated by Macro as jpeg image 
 
h. Use new jpeg image and data reports to check virus count 
 
i. Check each new image/data reports to determine if two or more 
touching virus particles were counted as one large particle 
 
1. Divide large particles by average single virus particle size, 
adjust reports as needed 
 
i. Determine Total Number of Virus Particles present in image 
 
i. Conduct same protocol as above for Cell-associated virus particles, 
except follow protocol on “Total Projection images” created above 
 
j. Determine Surface Area of Cells 
 
i. Open “Cell Region Projection image” created above in LSM Image 
Browser; make sure image separated into 3 color channel images 
 
k. Select appropriate color channel with just cells 
 
i. Red Channel: Cell surface labeled with Concanavalin A594 to appear 
red  
 
ii. Green Channel: Cell surface labeled with Concanavalin A488 to appear 
green 
 
l. Copy and Paste appropriate color channel into new image window as black 
and white image 
 
i. When prompted with dialog box, make sure image size and file type 
the same as original LSM image 
 
ii. Must create new image otherwise Macro will not interpret color image 
 
m. Manually adjust Brightness/Contrast and use Flood Fill Tool and Paintbrush 
Tool as needed to fill in cell bodies  
 
n. Convert image to Binary black and white image 
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i. Process – Binary – Threshold 
 
ii. May need to undo and make more adjustments if cell bodies are not 
accurately interpreted as area regions 
 
iii. In some cases may be easier to adjust non cellular regions as areas and 
minus them from total area of image to get cell body area  
 
o. Calculate surface area of cell bodies 
 
i. Analyze – Analyze Particles (on ImageJ menu bar) 
 
p. Organize/label data reports generated by Macro in Excel 
 
i. Reports record individual region number, individual region area, 
average region area, total area of regions, area of region as fraction of 
total area (units are in pixels) 
 
q. Save new image of counted cell body surface areas generated by Macro as 
jpeg image  
 
r. Once in Excel convert pixel2 to µm2 and calculate number of cell-associated 
virus particles per µm2 
 
7. Determine number of Cell Nuclei  
 
a. Open “Cell Region Projection image” created above in LSM Image Browser; 
make sure image separated into 3 color channel images 
 
b. Select Blue color channel with just cell nuclei 
 
c. Adjust Brightness/Contrast to eliminate background 
 
i. Hit “Yes” to Apply to all slices when prompted 
 
d. Make sure to return to first slice showing cell nuclei or Macro won’t run 
 
e. Run Blue Nuclei Macro (created by Jamie Chilton) 
 











B.1  Determination of the starting concentration of active virus (Cv0) in virus 
stocks and active virus particles delivered per cell (A).   
 
In a diluted titer assay, two-fold serial dilutions of VSV-G lacZ retrovirus and 
VSV-G lacZ lentivirus stocks were made in DMEM/BCS and Polybrene (8µg per mL).  
Serially diluted virus (1 mL per well) was used to transduce NIH 3T3 cells that had been 
seeded at 2 x 104 cells per well in 6-well plates the previous day.  The viral supernatants 
were removed 5 hours later and replaced with fresh medium.  Three days post 
transduction, the cells were fixed and stained for β-galactosidase activity with X-Gal [1].  
The number of colonies of lacZ+ NIH 3T3 cells were counted with the aid of a dissecting 
microscope, and multiplied by the dilution factor to determine CFU.  In parallel triplicate 
wells, the number of cells at the start of transduction was counted.   
The initial concentration of active retrovirus and lentivirus (Cvo) was estimated 








        [2] 
where CFU is the number of colony-forming units (determined from the diluted titer 
assay described above), ac is the average radius of NIH 3T3 cells (7 µm ), D is the 
diffusion coefficient of the virus (6.264 x 10-5 cm2/h), Nco is the total number of cells at 
the start of transduction, and I is an integrated function of time, the diffusion coefficient, 
the half-life of the virus, and the radius of the target cells [2, 3].  The integral I was 
evaluated and is described by the following equation:  
I h a t e dc
k tt dv= −∫ ( , )0 t           
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where the function h(ac,t) was derived by Shoup and Szabo, describing at time t, the flux 
of particles on each cell over the steady-state particle flux [4]. 
 The number of active retrovirus and lentivirus particles delivered per cell (A) was 
then estimated from the following relationship:  
A a DC Ic vo= η4                 [2] 
Results are the average of three independent experiments.   
.   
 






a c = 3µm a c = 4µm a c = 5µm a c = 7µm a c = 9µm a c = 11µm a c = 13µm a c = 15µm a c = 17µm a c = 19 µm a c = 21 µm 
5 0.515 0.521 0.528 0.541 0.554 0.568 0.581 0.595 0.609 0.622 0.636
0 1.009 1.018 1.027 1.046 1.064 1.083 1.102 1.121 1.14 1.159 1.178
5 1.493 1.504 1.515 1.537 1.56 1.582 1.605 1.628 1.651 1.674 1.697
0 1.967 1.979 1.992 2.018 2.043 2.069 2.095 2.121 2.147 2.174 2.2
5 2.431 2.446 2.46 2.488 2.517 2.545 2.574 2.603 2.632 2.661 2.69
0 2.887 2.903 2.918 2.949 2.98 3.011 3.043 3.074 3.105 3.137 3.169
5 3.335 3.351 3.368 3.401 3.434 3.468 3.501 3.535 3.569 3.602 3.636
0 3.774 3.792 3.809 3.844 3.88 3.915 3.951 3.986 4.022 4.058 4.094
5 4.205 4.223 4.242 4.279 4.316 4.354 4.391 4.429 4.466 4.504 4.542
0 4.628 4.647 4.667 4.706 4.745 4.784 4.823 4.862 4.902 4.941 4.981
5 5.043 5.064 5.084 5.124 5.165 5.206 5.247 5.288 5.329 5.37 5.411
0 5.451 5.472 5.493 5.535 5.577 5.62 5.662 5.705 5.747 5.79 5.833
5 5.851 5.873 5.895 5.938 5.982 6.026 6.069 6.113 6.158 6.202 6.246
0 6.244 6.267 6.289 6.334 6.379 6.424 6.469 6.515 6.56 6.606 6.652
5 6.63 6.653 6.676 6.722 6.768 6.815 6.861 6.908 6.955 7.002 7.049




















I h a t e dtc
k tt dv= −∫ ( , )0
Table B.1  Numerical values of the integral I for aVSV-G-pseudotyped lentivirus with a half-life of 19 hours.a
aValues of I are shown for various times of exposure of cells to VSV-G-pseudotyped lentivirus and various sizes (radius, ac) of 
target cells.  These values are used to calculate the initial concentration of active retrovirus at the start of infection (Cvo) and the 
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Table B.2  RFP-lacZ retrovirus stocks deliver a higher number of active viruses per cell to NIH 3T3 fibroblasts. a
aValues of Cvo and A were calculated based on 5 hours of exposure of NIH 3T3 cells to the virus stocks; stocks are 
VSV-G pseudotyped virus.
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